Curriculum Vitae

Richard Gentry Wilkerson, MD

Associate Professor, Department of Emergency Medicine University of Maryland School of Medicine

Date: March 2, 2024

Contact Information: Department of Emergency Medicine

110 South Paca Street, 6th Floor, Suite 200

Baltimore, MD 21201

gwilkerson@som.umaryland.edu

Education

1991 – 1996 B.S., Microbiology and Cell Science, University of Florida

2000 – 2004 M.D., University of Miami School of Medicine

Post-Graduate Training & Education

2004 - 2008	Residency, Emergency Medicine, SUNY-Downstate
2011 - 2012	Graduate, ACEP Teaching Fellowship, Dallas, TX

Certifications

2009 Diplomat, American Board of Emergency Medicine

2019 Diplomat, American Board of Emergency Medicine (Recertification)

Medical Licensures

2008	Inactive, New York
2010	Inactive, Florida

2010 Inactive, Medical Council of Tasmania, Australia

2012 Active, Maryland

Employment History

Academic Appointments

2008 - 2009	Clinical Assistant Professor, Department of Emergency Medicine, State
	University of New York-Downstate
2010 - 2012	Clinical Assistant Professor, College of Medicine, University of South
	Florida
2012 - 2020	Assistant Professor, Department of Emergency Medicine, University of
	Maryland School of Medicine
2020 - Present	Associate Professor, Department of Emergency Medicine, University of
	Maryland School of Medicine

Other Employment & Activities

1994 – 1995	Technician, University of Florida Organic Chemistry Laboratory
	Gainesville, FL
1996 – 1998 &	Research Technician, Department of Biochemistry, Univ. of
1999 - 2000	Florida; Gainesville, Florida
1997	Technician, Tissue Resource Center, Univ. of Florida;
	Gainesville, FL.
1998 - 1999	Medical Assistant, Jacksonville Pediatrics; Jacksonville, FL
1999	Coach, Episcopal High School Novice Girls Crew Program,
	Jacksonville, Florida
1999 - 2000	Coach, University of Florida Women's Crew Program, Gainesville,
	Florida

Professional Society Membership

2001 - 2012	Emergency Medicine Resident's Association
2010 - 2012	Florida College of Emergency Medicine
2001 - 2009	Diplomate, American College of Emergency Physicians
2009 – present	Fellow, American College of Emergency Physicians
2012 - 2023	Diplomate, American Academy of Emergency Medicine
2017 – present	General Member, Society for Academic Emergency Medicine
2020 – present	Member, American Society of Hematology
2021 - 2023	Associate Member, Society of Critical Care Medicine

Honors and Awards

1988	Eagle Scout, Florida Troop 2, Boy Scouts of America
2008	Resident Award Disaster Preparedness Division
2008	Resident Award Student Education Division
2008	eMedicine Contributor of the Month (December)
2015	Outstanding Teaching Attending Award, Univ. of Maryland Emergency Medicine
	Residency
2017	Outstanding Reviewer - American Journal of Emergency Medicine
2017	Western Journal of Emergency Medicine Distinguished Reviewer
2017	Western Journal of Emergency Medicine Distinguished Section Editor
2017	Top 20 Outstanding Abstract at Mediterranean Emergency Medicine Conference,
	Lisbon, Portugal
2018	Top Reviewer – American Journal of Emergency Medicine
2019	Clinician of the Year – Maryland Chapter of The American College of Emergency
	Physicians
2019	First Place – Best Scientific Writing or Technical Reporting, for "Advanced
	Management of Opioid Overdose in the Emergency Department," 40th Annual
	Specialized Information Publishers Association Awards
2019	Inducted into the inaugural class of the Peter Rosen Fellows Society, part of the
	National Foundation of Emergency Medicine
2022	Decision Editor of the Year - Clinical Practice and Cases in Emergency Medicine
2023	Decision Editor of the Year - Clinical Practice and Cases in Emergency Medicine

Clinical Activities

Clinical Expertise

Board certified in emergency medicine

Clinical, educational, and research focus in emergency medicine

\sim 1	A 4 • • 4 •
(linical	A ofivition
V IIIIII (AI	Activities

2008 – 2009 Site of Primary Practice: Kings County Hospital & SUNY-Downstate

Medical Center

 \sim 155,000+ & \sim 60,000 per year (patient volume)

Providing direct patient care and supervising resident trainees

75% clinical (140 hours per month), 25% educational

2010 Site of Primary Practice: Launceston General Hospital (Tasmania,

Australia)

~40,000 per year (patient volume)

Providing direct patient care (Consultant) and supervising trainees

(Registrars)

100% clinical (120 hours per month)

2010 – 2012 Site of Primary Practice: Tampa General Hospital

~100,000 per year (patient volume)

Providing direct patient care and supervising resident trainees

Director of Research

65% clinical (100 hours per month); 15% administrative; 20% research

2012 – present Site of Primary Practice: University of Maryland Medical Center

~55,000+ per year (patient volume)

Providing direct patient care and supervising resident trainees Coordinator for Clinical Research from Aug 2012-May 2016

Director Emergency Department Observation Services (Clinical Decision

Unit) from Nov 2012 - Jun 2015

Director of Clinical Research from May 2016-present

50-75% clinical (30-100 hours per month); 15% administrative; 10-35%

research

2020 – 2021 UMMS Teletriage Physician. Provides telemedicine support, entering

orders and discharging low-acuity patients triaged in UMMS EDs.

2020 – present Access Center Physician (ACP) Group. The ACP works in the call center

as the primary real-time medical liaison across all 14 hospitals in the University of Maryland Medical System, coordinating patient flow and transfers within and between hospitals to improve efficient matching of

healthcare resources to patient needs. 250 - 350 hours per year

2021 – present MTC Nocturnal Critical Care Support Physician, University of Maryland

Midtown Campus. Provides support for ED and ICU for critical procedures such as central access and airway management. 50 - 400

hours/year

Development of Clinical Programs

2012 - 2015	Developed protocols for UMMC Emergency Department Clinical
	Decision Unit and served as Director of Emergency Department
	Observation Services
2016	Created and implemented UMMC "Emergency Department Overdose
	Response Program"
2017	Created and implemented UMMC "Guideline for Initiation of
	Buprenorphine in the Emergency Department"
2017	Created "Guideline for Emergency Department Care of Patient with Sickle
	Cell Vaso-Occlusive Crisis"
2019 – present	Clinical Leader to Develop Multi-Disciplinary Sickle Cell Program (0.2
	FTE)
2020	Member: COVID-19 Remote Patient Monitoring Pilot Program
	Development Team
2023	Physician lead: University of Maryland Medical System (UMMS): Take
	Home Naloxone Program

Administrative Service

Institutional Service

Departmental Service

2012 – present	Member, UMSOM Department of Emergency Medicine (UMDEM) Peer
	Review Committee
2012 – present	Faculty interviewer for prospective resident applicants (8-13 days per
	year), participate in Resident Selection Meeting
2012 – present	Member, UMDEM Education Committee
2016 – present	Member of UMDEM Resident Clinical Competency Committee
2016 – present	Chair, Program Evaluation Committee
2022 – present	UMDEM Prospective Faculty Interviewer
2022 – present	UMDEM Departmental Reviewer for Human Subjects Research
2023	UMDEM CME Compensation Committee
2023 – present	Reviewer, UMDEM Departmental Pilot Grant Review Committee
2024 – present	Member, Department of Emergency Medicine Appointment, Promotion
	and Tenure of Faculty (APT) Committee
TT '4 10 '	

Hospital Service

2004 - 2009	Member, Continuous Quality Improvement Committee; Kings County
	Hospital
2004 - 2009	Member, CBRNE Disaster Response Team: Kings County Hospital
2011 - 2012	Member, Pharmacy & Therapeutics Committee, Tampa General Hospital
2013	Member, 2-Midnight Rule Committee, University of Maryland Medical
	Center
2013 - 2014	Member, University of Maryland Medical Center Denials Committee
2017 – present	Member, UMMC Pharmacy & Therapeutics Committee

2017 – 2022	Member, UMMC Opioid Task Force 2018-2022 Co-Chair
2017 – present 2019 – present	Member- Professional Assistance Committee, UMMC Clinical Leader: UMMC Sickle Cell Disease Multi-Disciplinary Care Program
2020 – 2022 2022 – present	Member, UMD COVID-19 Research Advisory Task Force Co-Chair UMMC Opioid Safety Council
2023 – present	Entity Director, University of Maryland Medical System Overdose Response Program
SOM Service	
2013 - 2022	University of Maryland School of Medicine Council,
	2013-2015 Alternate Member
2014	2015-2022 Department Representative
2014 – present 2016 – present	Admissions Interviewer, University of Maryland School of Medicine Faculty Mentor, Eva Dodge House (UMSOM)
2010 Present	Faculty Mentor for Eva Dodge House Community Service Chair &
2016	Committee Lydge 20th Medical Student Research Day, Sontomber 14, 2016
2016 2016	Judge, 39th Medical Student Research Day, September 14, 2016 Coater, Class of 2020 White Coat Ceremony (November 2016)
2017	Judge, 40th Medical Student Research Day, September 28, 2017
2017	Coater, Class of 2021 White Coat Ceremony (November 2017)
2018	Coater, Class of 2022 White Coat Ceremony (November 2017) Coater, Class of 2022 White Coat Ceremony (November 2018)
2019	Coater, Class of 2023 White Coat Ceremony (November 2019)
2020 - 2023	Member, University of Maryland, Baltimore Faculty Senate
2020 2023	Judge, 43rd Medical Student Research Day, November 12-13, 2020
2021 – present	Core Educator, UMSOM Medical Education Leadership Academy (MELA)
2021	Coater, Class of 2025 White Coat Ceremony (August 2021)
2021	Judge, 44th Medical Student Research Day, November 15-16, 2021
2022 – present	Full Committee Member, UMSOM Committee on Admissions
2022 present 2022	Pinner, Class of 2024 Student Clinician Ceremony and Family Celebration
2022	(April 2022)
2022	Judge, 45th Medical Student Research Day, November 16, 2022
2023	UM Scholars Program – Application Reviewer
2023	Pinner, Class of 2025 Student Clinician Ceremony and Family Celebration (April 2023)
2023	Coater, Class of 2027 White Coat Ceremony (August 2023)
2023	Office of Student Research Mid-Summer Retreat Roundtable Discussion
2023	Judge, 46 th Medical Student Research Day, November 29, 2023
2024	UM Scholars Program – Application Reviewer

International Service 2020 – 2023 Program Advisory Committee Member, Canadian Physicians for Aid and Relief (CPAR)

National Service	
2012	Ad Hoc Reviewer, The African Journal of Emergency Medicine (1x/year)
2014 – present	Ad Hoc Reviewer, Western Journal of Emergency Medicine (20-40x/year)
2014 – present	Co-Editor, Disaster Medicine Section, Western Journal of Emergency
2014 – present	Medicine
2014 - 2021	Member, American Academy of Emergency Medicine (AAEM) Education
2014 - 2021	Committee
2015 - 2021	Member, AAEM Scientific Assembly Planning Committee
2013 2021	2016-2017 Chair of Pecha Kucha Planning Subcommittee
	2017-2020 Chair of Pre-Conference Program
	2020 Vice Chair AAEM Scientific Assembly Planning Committee
	2021 Advisor to AAEM Scientific Assembly Planning Committee
2016 – present	Ad Hoc Reviewer, American Journal of Emergency Medicine (12x/year)
2010 – present 2017	Council of Residency Directors (CORD) 2017 Academic Assembly
2017	Abstract Reviewer
2018	Moderator, Wine & Cheese Poster Session: CORD 2017 Academic
2016	Assembly Advances in Education Research and Innovations Forum
2018	Abstract Reviewer, ACEP Research Forum 2018
	·
2018 – present 2018 – 2021	Member, SAEM Research Committee
	Member, AAEM Clinical Practice Committee
2018 - 2020	AAEM Scientific Assembly Young Physicians Section (YPS) Poster
2010 2020	Competition Chair
2018 - 2020	AAEM Scientific Assembly Track Moderator
2018 – 2019	SAEM Annual Meeting: Oral Abstract Moderator
2018 – present	Member, CORD Research & Scholarly Productivity Committee
2018 – 2020	ACEP Research Section: Alternate Councilor
2019 – present	Senior Editorial Consultant, American Journal of Emergency Medicine
2019 – present	Member, Emergency Department Sickle Cell Care Coalition (EDSC3)
2010	2020-present Board of Governors
2019	Abstract Reviewer, ACEP Research Forum 2019
2019	Ad Hoc Reviewer, BMJ Case Reports (1x/year)
2019	Ad Hoc Reviewer, JAMA Open (1x/year)
2019 – present	Ad Hoc Reviewer, Annals of Internal Medicine (2x/year)
2020	Ad Hoc Reviewer, PLOS One (1x/year)
2020	Ad Hoc Reviewer, Journal of Emergency Nursing (1x/year)
2020	Abstract Reviewer, ACEP Research Forum 2020
2020 – present	Ad Hoc Reviewer, BMJ Open (1x/year)
2020 – present	Ad Hoc Reviewer, Journal of Emergency Medicine (1x/year)
2020 - 2021	Decision Editor, Clinical Practice and Cases in Emergency Medicine
2020 - 2022	ACEP Research Section: Councilor
2021	Abstract Reviewer, ACEP Research Forum 2021 Special Edition COVID
2021 – present	Deputy Editor, Clinical Practice and Cases in Emergency Medicine
2022 – present	Maryland ACEP: Councilor for ACEP Council Meeting
2022	Moderator & Judge for AAEM Scientific Assembly AAEM / RSA and
	Western Journal of Emergency Medicine Population Health Research
	Competition, Baltimore, MD

R. Gentry Wilkerson, MD

2022	Abstract Reviewer, ACEP Research Forum 2022
2022	Ad Hoc Reviewer, Chest (1x/year)
2022	ACEP Scientific Assembly: Research Forum 2022 Moderator, San
	Francisco, CA
2022 - 2024	ACEP Research Section: Secretary
2023	Abstract Reviewer, ACEP Research Forum 2023
2023 – present	Director, Scholars Mentors Program, National Foundation of Emergency
	Medicine
2024 – present	Member, SAEM Program Committee
2024 – present	Member, SAEM Grants Committee

Local Service

2011 – 2012 Member, Florida College of Emergency Physicians Academic Affairs

Committee

Teaching Service

Undergraduate Student Teaching

2018	Mentor, Summer Research
	2 undergraduates, daily contact during summer
2019	Mentor, Summer Research
	2 undergraduates, daily contact during summer
2021	Mentor, Summer Clinical Experience
	1 undergraduate, weekly contact during the summer

Medical Student Teaching

Micuical Student 16	acming
2008 - 2009	Faculty preceptor for First Year Medical School Class: Essentials of
	Clinical Medicine I at SUNY- Downstate
2012 - 2015	Faculty preceptor for Introduction to Clinical Medicine for Second Year
	Medical Students (ICM-II); University of Maryland School of Medicine
2014 – present	Faculty Mentor for Foundations in Research and Critical Thinking
2014 – present	Faculty Small Group Leader for MS2 Cardiology Sessions
2017 - 2019	Mentor: Student Ambassador Program at AAEM Scientific Assembly
2020	Faculty Small Group Leader for MS2 Pulmonology Sessions
2020	Faculty Small Group Leader for MS1 Hypothesis Testing
2022	Faculty Instructor- Multisystem – Toxicology Small Groups, February 24,
	2022
2022	Faculty Instructor- Introduction to Ultrasound for MS2, August 4, 2022
2022	Faculty Instructor- Multisystem Course for MS2,
	Cardiac/Pulmonary/Renal, October 27, 2022
2023	Faculty Instructor – Clinical Introduction to First Year (CLIFY) – Opioid
	Overdose, August 1, 2023
2023	Panelist – Mentor Workshop for First Year Medical Students, October 2,
	2023
2023	Mock Residency Interviews (3 medical students, October 2023)

Resident Teaching	
2010 - 2012	Faculty facilitator for Resident Journal Club- USF EM Residency Program
2011 - 2012	Faculty facilitator for Evidence-Based Medicine/Critically Appraised
2012	Topic Lectures for USF EM Residency Program
2013 – present	University of Maryland Department of Emergency Medicine Resident Grant Committee
2014 – present	Faculty facilitator, University of Maryland Emergency Medicine
	Residency Journal Club
2015	Panelist, 14th Annual Resident Research Forum June 10, 2015, University
	of Maryland Emergency Medicine Residency
2016 – present	Assistant Residency Program Director for Emergency Medicine
2016	Panelist, 15 th Annual Resident Research Forum June 8, 2016, University
	of Maryland Emergency Medicine Residency
2017	Faculty: Masters in Emergency Medicine; Apollo GlenEagles Hospital,
	Kolkata, India
2017	Panelist, 16 th Annual Resident Research Forum June 14, 2017, University of Maryland Emergency Medicine Residency
2018	Panelist, 17 th Annual Resident Research Forum June 13, 2018, University
	of Maryland Emergency Medicine Residency
2021	Panelist, 19th Annual Resident Research Forum June 2, 2021, University
	of Maryland Emergency Medicine Residency
2022	Greater Chesapeake Conference- developed and led a station on the topic-
	Substance abuse. Attended by ~200 residents and medical students from
	The University of Maryland, Georgetown, George Washington, Hopkins,

Post-Graduate Teaching

2012	Faculty: Emergency Medicine Practices and Advance Clinical
	Therapeutics (EMPACT) Course, All India Institute of Medical Sciences
	(AIIMS), Delhi, India
2017 – present	Faculty for Post-Doctorate Research
	1 post-graduate per year (2 total) - >200 contact hours per year
2023	Faculty: National Foundation of Emergency Medicine/Eureka Conference

San Diego, CA

and York.

Mentoring

High School Students	
----------------------	--

2018 Dildane, Maria

Undergraduate Students

\mathcal{C}	
2018	Carrigan, Christian (University of Florida)
2019	Croft, Jade (Florida State University)
2021	Smiley, Jasmine (Frostberg University)
2022	Brown, Casev (Lovola University, Maryland)

2022	Raman, Ashley (Johns Hopkins University)
2022 – present	Brecher, Vanesa (University of Maryland, College Park)
2023 – present	*Capati, Ariana (University of Maryland, College Park)
2023 – present	*Ufoh, Annice (University of Maryland, College Park)
2023	Nepenthe, Dzifa (Wellesley College)
	* as part of the UM Scholars Program

Post-Graduate Students

1 001 010000000000000000000000000000000	1110
2015 - 2021	del Ninno, Thomas
2018	Gautum, Shruti
2018	Ruehle, Sarah
2018 - 2019	El Sibai, Rayan
2018 - 2021	Isaacs, Rachel
2018 - 2023	Lasko, Kyra
2019	Schwartz, Andrew
2019	Weingrad, Aaron
2019 - 2022	Annous, Youssef
2021	Mahmous, Ayed
2021 - 2022	Malherbe, Petrus
2022 - 2023	Dakassian, Alik

Medical Students

2021 - 2022	Auville, Kurt
2021 - 2022	Coleman, Benjamin
2021 - 2022	van Biesen, Lexi
2022 – present	Harris, Andrea
2022 - 2023	Yoon, Insun
2022 - 2023	LaBonte, Lindsie
2022 - 2023	Sikorski, Michael
2022 – present	Schwartz, Andrew
2023 – present	Rallo, Melissa
2023 – present	Mondle, Jennifer
2023 – present	De Leon, Ashlee
2024 – present	Escobal, Dominic
2024 – present	Genuit, Andrew
2024 – present	Jain, Sara

International Residents

2022	Nimnuan, Waratchaya (Ramathibodi Hospital; Bangkok, Thailand)
2022	Preechakul, Pacharaporn (Ramathibodi Hospital; Bangkok, Thailand)
2023	Deevijit, Chawanlak (Chiang Mai University; Chiang Mai, Thailand)
2023	Ueareekul, Supapilai (Chiang Mai University; Chiang Mai, Thailand)
2023	Chotiratanasak, Saran (Chiang Mai University; Chiang Mai, Thailand)
2023	Pumguman, Jidapa (Somdech Phra Pinklao Hospital; Bangkok, Thailand)
2024	Chumvanichaya, Kritsada (Ramathibodi Hospital; Bangkok, Thailand)
2024	Danrungrot, Teeravit (Chiang Mai University; Chiang Mai, Thailand)

Wongnang, Haruetai (Chiang Mai University; Chiang Mai, Thailand)
Chalongkulsak, Thanawadee (Chiang Mai University; Chiang Mai,

Thailand)

Grant/Contract Support

Active Grants

2021 – present National Foundation of Emergency Medicine Scholars-Mentor Program

2-year funding grant (\$30,000/yr) with the objective to stimulate, help train, and produce an academic commitment to Emergency Medicine research through a partnership and sponsorship of industries concerned with products useful in the diagnostics and practice of Emergency

Medicine. Role: Mentor

Funding: \$10,000 per year for 2 years

2022 – present UMSOM Department of Emergency Medicine Grant

Project: Sepsis in Low-resource Settings: Identifying Barriers Related to

Infectious Illness Management in Fitche, Ethiopia

Role: Principal Investigator

Funding: \$15,000

2023 – present Maryland Department of Health Office of Preparedness and Response

Grant

Project: Xylazine and Nitazene Testing in Non-Fatal Opioid Overdoses

Role: Principal Investigator

Funding: \$47,228

Active Contracts

2023 – present ARREST PNEUMONIA: ARRest RESpiraTory failure due to

PNEUMONIA

Role: Site Sub-Investigator

Study Chairs: Joseph Levitt, MD & Emir Festic, MD Funding by NHLBI Grant 1UG3HL141722-01A1

2023 – present CARPO: A Randomized, Double-Blind, Placebo Controlled Dose-

Ranging Study of Auxora in Patients with Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome

Role: Site Principal Investigator Sponsor: CalciMedica, Inc.

2023 – present TNX-1300 (Cocaine Esterase)

TNX-CE-C1202: A Single-Blind, Randomized Study Comparing the Efficacy and Safety of a Single Dose of TNX-1300 to Placebo with Usual Care (UC) for the Treatment of Signs and Symptoms of Acute Cocaine

Intoxication in Emergency Department (ED) Subjects

Role: Site Principal Investigator Sponsor: Tonix Pharmaceuticals, Inc.

2024 – present A Phase 4 Study Using a Test-Negative Design to Evaluate the

Effectiveness of a 20-Valent Pneumococcal Conjugate Vaccine against

Vaccine-Type Radiologically-Confirmed Community-Acquired

Pneumonia in Adults ≥65 Years of Age

Role: Site Principal Investigator

Sponsor: Pfizer, Inc.

Completed Grants

2015 UMSOM Department of Emergency Medicine Grant

Project: The Accuracy of ED-Physician Performed Ultrasound to Identify Vascular Structures at the Three Sites Traditionally Used for Paracentesis

Role: Principal Investigator

Funding: \$3170

2016 Maryland Industrial Partnerships (MIPS) Grant

Project: Evaluation of a Novel Gastrostomy Procedural Method

Role: Principal Investigator Funding: \$90,000

2016 UMSOM Department of Emergency Medicine Grant

Project: Evaluation of Loop Drainage Technique versus Standard Incision and Drainage for Treatment of Simple Soft Tissue Abscesses

Role: Principal Investigator Funding: \$10,000

2016 UMSOM Department of Emergency Medicine Grant

Project: Comparative Usability Study of Naloxone Autoinjector versus Improvised Intranasal Delivery System in an At-Risk Population

Role: Principal Investigator Funding: \$10,000

2017 Maryland Industrial Partnerships (MIPS) Grant

Project: Evaluation of a Novel Gastrostomy Procedural Method

Role: Principal Investigator Funding: \$100,000

2018 – 2019 ACEP/Pfizer Independent Grants for Learning & Change (IGLC)

Project: Sickle Cell Disease Patient Navigation Program

Role: Project Lead & Oversight

Funding: \$49,991 for nurse salary support

2019 – 2022 2R44DK115325-02A1, NIDDK

Percutaneous Ultrasound Gastrostomy: Clinical Evaluation of a Novel

Method for Feeding Tube Placement

A pilot clinical safety study supporting dissemination of a novel method for safer, more accessible placement of gastrostomy feeding tubes and to develop a rigorous Human Factors-informed training program for the use of the novel Point- of-Care Ultrasound Magnet Aligned Gastrostomy

(PUMA-G) device.

Role: Principal Investigator Funding: \$1.2 million

Completed Contracts

Department & ICU Role: Principal Investigator (5%) Sponsor: EZ-NG AST-111: (Sapphire) Evaluation of Novel Biomarkers from Acutely Ill Patients at Risk for Acute Kidney Injury Role: Site Principal Investigator (5%) Sponsor: Astute Medical Inc. Study Principal Investigator: John Kellum, MD ACE React: Evaluation of Ecallantide for the Acute Treatment of ACE Inhibitor Induced Angioedema Role: Site Co-Investigator (5%) Sponsor: Dyax Corp. 2014 – 2015 CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD Study Principal Investigator: Alan Kimura, MD, PhD RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase Ill study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator: (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator: (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator: Terry Plasse, MD ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (5%) Sponsor: National Institute of Neurological Disorders and Stroke ML-3441-306: A Phase 3, M	2011 – 2012	EZ-NG: Evaluation of a new device, EZ-NG TM , for rapid bedside verification of placement of nasogastric tubes in the Emergency
Sponsor: EZ-NG AST-III: (Sapphire) Evaluation of Novel Biomarkers from Acutely III Patients at Risk for Acute Kidney Injury Role: Site Principal Investigator (5%) Sponsor: Astute Medical Inc. Study Principal Investigator: John Kellum, MD ACE React: Evaluation of Ecallantide for the Acute Treatment of ACE Inhibitor Induced Angiocdema Role: Site Co-Investigator (5%) Sponsor: Dyax Corp. CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator: David T. Huang, MD, Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorder		
AST-111: (Sapphire) Evaluation of Novel Biomarkers from Acutely III Patients at Risk for Acute Kidney Injury Role: Site Principal Investigator (5%) Sponsor: Astute Medical Inc. Study Principal Investigator: John Kellum, MD 2011 – 2012 ACE React: Evaluation of Ecallantide for the Acute Treatment of ACE Inhibitor Induced Angioedema Role: Site Co-Investigator (5%) Sponsor: Dyax Corp. 2014 – 2015 CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator: Marco Metra and John Teerlink ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator: Marco Metra and John Teerlink ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		Role: Principal Investigator (5%)
Patients at Risk for Acute Kidney Injury Role: Site Principal Investigator (5%) Sponsor: Astute Medical Inc. Study Principal Investigator: John Kellum, MD 2011 – 2012 ACE React: Evaluation of Ecallantide for the Acute Treatment of ACE Inhibitor Induced Angioedema Role: Site Co-Investigator (5%) Sponsor: Dyax Corp. 2014 – 2015 CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink 2014 – 2017 ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator: Thermo Fisher Study Principal Investigator: David T. Huang, MD, Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, 2015 – 2017 Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRy embolism from the Emergency Department Role: Site Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRy embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetira		Sponsor: EZ-NG
Role: Site Principal Investigator (5%) Sponsor: Astute Medical Inc. Study Principal Investigator: John Kellum, MD ACE React: Evaluation of Ecallantide for the Acute Treatment of ACE Inhibitor Induced Angioedema Role: Site Co-Investigator (5%) Sponsor: Dyax Corp. CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Screlaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMericux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator: Terry Plasse, MD MERCURY - PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2011 - 2012	` • • · · · · · · · · · · · · · · · · ·
Sponsor: Astute Medical Inc. Study Principal Investigator: John Kellum, MD ACE React: Evaluation of Ecallantide for the Acute Treatment of ACE Inhibitor Induced Angioedema Role: Site Co-Investigator (5%) Sponsor: Dyax Corp. 2014 – 2015 CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink 2014 – 2017 ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY - PE: Multicenter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		• • •
Study Principal Investigator: John Kellum, MD ACE React: Evaluation of Ecallantide for the Acute Treatment of ACE Inhibitor Induced Angioedema Role: Site Co-Investigator (5%) Sponsor: Dyax Corp. 2014 – 2015 CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator (3%) Sponsor: NIGMS, BioMericux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, 2014 – 2017 Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY - PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRy embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 — 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
ACE React: Evaluation of Ecallantide for the Acute Treatment of ACE Inhibitor Induced Angioedema Role: Site Co-Investigator (5%) Sponsor: Dyax Corp. 2014 – 2015 CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapics, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink 2014 – 2017 ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY - PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		1
Inhibitor Induced Angioedema Role: Site Co-Investigator (5%) Sponsor: Dyax Corp. 2014 – 2015 CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Screlaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink 2014 – 2017 ProAcT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, 2015 – 2017 Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY - PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRy embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 — 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2011 2012	•
Role: Site Co-Investigator (5%) Sponsor: Dyax Corp. CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2011 – 2012	
Sponsor: Dyax Corp. CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
2014 – 2015 CAMEO: ACE-I-Induced Angioedema Study Measuring Efficacy of Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink 2014 – 2017 ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY - PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 — 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
Icatibant Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink 2014 – 2017 Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, 2015 – 2017 Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2014 - 2015	1 1
Role: Site Principal Investigator (2%) Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink 2014 – 2017 ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRy embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2014 - 2013	
Sponsor: Shire Orphan Therapies, Inc Study Principal Investigator: Alan Kimura, MD, PhD 2014 – 2016 RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink 2014 – 2017 ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
Study Principal Investigator: Alan Kimura, MD, PhD RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
RELAX2: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		1 1 1
phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY-PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2014 - 2016	• •
Role: Site Sub-Investigator (PI: S. Gottlieb) Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, 2015 – 2017 Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		•
Sponsor: Novartis Study Principal Investigator: Marco Metra and John Teerlink 2014 – 2017 ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, 2015 – 2017 Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		when added to standard therapy in acute heart failure patients
Study Principal Investigator: Marco Metra and John Teerlink 2014 – 2017 ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, 2015 – 2017 Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRy embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		Role: Site Sub-Investigator (PI: S. Gottlieb)
2014 – 2017 ProACT: Procalcitonin Antibiotic Consensus Trial Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 — 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		Sponsor: Novartis
Role: Site Principal Investigator (3%) Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
Sponsor: NIGMS, BioMerieux, Thermo Fisher Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2014 - 2017	
Study Principal Investigator: David T. Huang, MD, Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
2015 – 2017 Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		•
(Ondansetron 24 mg Bimodal Release Tablets) for vomiting due to Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2015 2015	•
Presumed Acute Gastroenteritis or Gastritis Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2015 – 2017	
Role: Site Principal Investigator (5%) Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		` /
Sponsor: Redhill BioPharma, LTD Study Principal Investigator: Terry Plasse, MD 2016 MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
Study Principal Investigator: Terry Plasse, MD MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
MERCURY- PE: MulticEnter trial of Rivaroxaban for early disCharge of pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		<u>.</u>
pUlmonaRY embolism from the Emergency Department Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2016	• • •
Role: Site Principal Investigator (2%) Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2010	·
Sponsor: Janssen 2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
2016 – 2018 ESETT: Established Status Epilepticus Treatment Trial: A multicenter, randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		- · · · · · · · · · · · · · · · · · · ·
randomized, blinded, comparative effectiveness study of fosphenytoin, valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke	2016 - 2018	<u> </u>
valproic acid, or levetiracetam in the ED treatment of patients with benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
benzodiazepine-refractory status epilepticus. Role: Site Sub-Investigator (Site PI: J. Hopp) Sponsor: National Institute of Neurological Disorders and Stroke		
Sponsor: National Institute of Neurological Disorders and Stroke		
		Role: Site Sub-Investigator (Site PI: J. Hopp)
2017 – 2018 ML-3441-306: A Phase 3, Multicenter, Randomized, Double-Blind,		· ·
	2017 - 2018	ML-3441-306: A Phase 3, Multicenter, Randomized, Double-Blind,

R. Gentry Wilkerson, MD

	Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects with Community-Acquired Bacterial Pneumonia
2017 – 2018	Role: Site Principal Investigator (2%) Sponsor: Melinta SGSC-005: A Phase 2 Study of the Safety and Effectiveness of SANGUINATE in the Treatment of Vaso-occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults with Sickle Cell Disease
2017 – 2019	Role: Site Principal Investigator (5%) Sponsor: Prolong Pharmaceuticals, LLC RESET: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of Rivipansel (GMI- 1070) In The Treatment Of Vaso-Occlusive Crisis In Hospitalized Subjects With Sickle Cell Disease
2017 – 2019	Role: Site Principal Investigator (10%) Sponsor: Pfizer RESET: An Open-Label Extension Study To Evaluate The Safety Of Rivipansel (GMI-1070) In the Treatment of One or More Vaso-Occlusive Crises In Hospitalized Subjects With Sickle Cell Disease Role: Site Principal Investigator (3%)
2017 – 2019	Sponsor: Pfizer STOP-CP: High-Sensitivity Cardiac Troponin T To Optimize Chest Pain Risk Stratification Role: Site Principal Investigator (15%), Member Steering Committee Sponsor: Roche Study Principal Investigator: Brandon R. Allen, MD & Simon A. Mahler,
2019 – 2021	MD (Site-PI) PI: R. Wilkerson (3%) Use of Methylene Blue in Acquired Methemoglobinemia: Prospective Observational Registry (metHb)
2019 – 2020	Funding Source: Hospital Quality Foundation (Site-PI) PI: R. Wilkerson (3%) The VItamin C, Thiamine And Steroids in Sepsis (VICTAS) Study
2019 – 2020	Subaward of Grant Agreement #2393 The Marcus Foundation (Site-PI) PI: R. Wilkerson (5%) A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination
2019 – 2020	With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection Funding Source: Janssen (Site-PI) PI: R. Wilkerson (5%) A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Patients With Influenza A Infection

2020	Funding Source: Janssen (Site-PI) PI: R. Wilkerson (5%) A Phase 2, Randomized, Double-blind, Placebo-controlled Study to
	Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects with Recently Diagnosed COVID-19 Compared to Standard of
2020 – 2021	Care Treatment (Site-PI) PI: R. Wilkerson
	A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy with Monoclonal Antibodies in Participants with Mild to Moderate COVID-19 Illness (BLAZE-4)
2020	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
	Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2
	Role: Site Sub-Investigator Site PI: Joel Chua
2020 - 2021	(Site-PI) PI: R. Wilkerson
	A Phase 2 Study to Assess the Virologic Efficacy of
	REGN10933+REGN10987 Across Different Dose Regimens in
2020 2021	Outpatients with SARS-CoV-2 Infection
2020 - 2021	A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of
	Hospitalized Patients with COVID-19
	Role: Site Sub-Investigator
	Site PI: Shivakumar Narayanan
2020 - 2021	(Site-PI) PI: R. Wilkerson
	BLAZE-4: A Randomized, Double-blind, Placebo-Controlled, Phase 2/3
	Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479
	in Participants with Mild to Moderate COVID-19 Illness Sponsor: Eli Lilly
2020 - 2022	(Site-PI) PI: R. Wilkerson
2020 2022	Regeneron-2067: A Master Protocol Assessing The Safety, Tolerability,
	And Efficacy Of Anti-Spike (S) SARS-Cov-2 Monoclonal Antibodies For
	The Treatment Of Ambulatory Patients With COVID-19
0004	Sponsor: Regeneron
2021 - 2022	(Site-PI) PI: R. Wilkerson
	BGE-175-201: A Multicenter, Randomized, Double-blind, Placebo- controlled, Phase 2 Study to Investigate the Efficacy and Safety of
	Asapiprant in Hospitalized Adults With COVID-19
	Sponsor: BioAge
2021 - 2022	(Site-PI) PI: R. Wilkerson
	The EMPATHY Trial: MP0420-CP302 (CSKO136A12201J)
	A randomized, double-blind, placebo-controlled, multicenter study of
	ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19
	CO 4 ID-17

R. Gentry Wilkerson, MD

2021 2022	Sponsor: Novartis
2021 - 2022	(Site-PI) PI: R. Wilkerson
	A Phase 3b, Randomized, Double-blind, Placebo-controlled, Multicenter
	Study to Evaluate the Treatment Effect of Voxelotor on Neurocognitive
	Function in Pediatric Participants 8 to < 18 Years of Age with Sickle Cell
	Disease
	Sponsor: Global Blood Therapeutics, Inc.
2021 - 2022	(Site-PI) PI: R. Wilkerson
	EPH-OBS-US-001: EPH Septic Shock Observational Study (ESSOS)
	Sponsor: Endpoint Health, Inc.
2019 - 2022	COMPARE-VOE: A Comparison of Individualized vs. Weight Based
	Protocols to Treat Vaso-Occlusive Episodes in Sickle Cell Disease
	Role: Site Principal Investigator (8%), Member Steering Committee
	Study PIs: Paula Tanabe, Ph.D, CCC PI and Huiman Barnhart, Ph.D., DCC PI
	Funding by NHLBI Grant 1U24HL137907-01A1
2021 - 2022	(Site-PI) PI: R. Wilkerson
	INSIGHT Protocol Number: 012
	Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC)
	An International Multicenter, Randomized, Double-Blind, Placebo-
	Controlled Trial of the Safety and Efficacy of Anti-Coronavirus
	Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult
	Outpatients in Early Stages of COVID-19
	Sponsor: Leidos Biomedical Research, Inc
	Frederick National Laboratory for Cancer Research
	Support to the National Institute of Allergy and Infectious Diseases
2023 – present	IDS-22-BACT001 Prospective Blood Culture Collection of Patients with
r	Suspected Cases of Bloodstream Infection (BSI)
	Role: Principal Investigator
	Sponsor: Becton, Dickinson and Company
	Spensor. Better, Brownson and Company

Publications

Peer-Reviewed Journal Articles

- 1. **Wilkerson RG**, Sinert RH. The Use of Paracentesis in the Assessment of the Patient with Ascites. Ann Emerg Med 2009; 54:465-468 [peer-reviewed summary of another article]
- 2. **Wilkerson RG**, Stone MB. Sensitivity of Bedside Ultrasound and Supine Anteroposterior Chest Radiographs for the Identification of Pneumothorax After Blunt Trauma. Acad Emerg Med 2010; 17:11-17 [peer-reviewed]
- 3. **Wilkerson RG**. Getting the Blues at a Rock Concert: A Case of Severe Methaemoglobinaemia. Emerg Med Austral 2010; 22:466-469 [case report]
- 4. **Wilkerson RG**. Angioedema In The Emergency Department: An Evidence-Based Review. Emerg Med Pract. 2012; 14(11):1–24. [indexed in PubMed]
- 5. Kashani K, Al-Khafaji A, Ardiles T, ..., **Wilkerson R**, Zacharowski K and Kellum J. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury.

- Crit Care. BioMed Central Ltd; 2013 Feb 6;17(1):R25. [multicenter study peer-reviewed]
- 6. Koo LW, Layson-Wolf C, Brandt N, Hammersla M, Idzik S, Rocafort T, Tran D, Wilkerson RG, and Windermuth B. Qualitative Evaluation of a Standardized Patient Clinical Simulation for Nurse Practitioner and Pharmacy Students. Nurse Ed Prac. 2014; 14(6):740-746 [peer-reviewed]
- 7. **Wilkerson RG**, Kim HK, Windsor TA, Mareiniss DP. The Opioid Epidemic in the United States. Emerg Med Clin North Am. 2016; 34(2):e1-e23 [indexed in PubMed]
- 8. **Wilkerson RG**, Lemon C. Blast Injuries. Trauma Reports. May 2016 [CME Publication] [not indexed in PubMed]
- 9. Adebayo O, **Wilkerson RG**. Angiotensin-converting enzyme inhibitor–induced angioedema worsened with fresh frozen plasma. Am J Emerg Med. 2017; 35(1):192.e1–192.e2 (ePub June 28, 2016) [case report]
- 10. Crouter AJ, Abraham MK, **Wilkerson RG**. Emphysematous Pyelonephritis in a Renal Allograft. Am J Emerg Med 2017; 35(3): 520.e1–520.e2 (ePub Sep 22, 2016) [case report]
- 11. Huang DT, Angus DC, Chang CCH, et al. Design and rationale of the Procalcitonin Antibiotic Consensus Trial (ProACT), a multicenter randomized trial of procalcitonin antibiotic guidance in lower respiratory tract infection. BMC Emerg Med 2017; 17(1):25 [collaborator multicenter trial]
- 12. Ham J, Ordonez E, **Wilkerson RG**. Care of Acute Gastrointestinal Conditions in the Observation Unit. Emerg Med Clin North Am. 2017; 35(3):571-587 [indexed in PubMed]
- 13. Ostermann M, McCullough PA, Forni LG, et al. Kinetics of Urinary Cell Cycle Arrest Markers for Acute Kidney Injury Following Exposure to Potential Renal Insults. Crit Care Med. 2018;46(3):375-383. [collaborator multicenter investigation]
- 14. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. N Engl J Med. 2018;379(3):236-249. [collaborator ProACT Investigators]
- 15. Wilkerson RG, Gatz JD, Liu ML. Advanced Management of Opioid Overdose in the Emergency Department. EM Reports 2018; 39(6):1-15 [not indexed in PubMed]
- 16. **Wilkerson RG**, Pustavoitau A, Carolan H, et al. Percutaneous Ultrasound Gastrostomy: A Novel Device and Bedside Procedure for Gastrostomy Tube Insertion Using Magnetic and Ultrasound Guidance. J Med Dev. 2019;13(2):024501 [peer reviewed]
- 17. **Wilkerson RG** and Ogunbodede AC. Hypertensive Disorders of Pregnancy. Emerg Med Clin North Am. 2019;37(2):301-316. [indexed in PubMed]
- 18. Li M, Martinelli AN, Oliver WD, **Wilkerson RG.** Evaluation of Ketamine for Excited Delirium Syndrome in the Adult Emergency Department. Am J Emerg Med. 2019; 58(1): 100-105. [indexed in PubMed]
- 19. Joannidis M, Forni LG, Haase M, et al. Use of Cell Cycle Arrest Biomarkers in Conjunction With Classical Markers of Acute Kidney Injury. Crit Care Med. 2019;47(10):e820-e826. [collaborator secondary analysis of multicenter trial]
- 20. **Wilkerson RG**, Yuan S, and Windsor TA. Trauma in Pregnancy: A Comprehensive Overview. Trauma Reports. 21:3, May 2020; [CME Publication] [not indexed in PubMed]

- 21. **Wilkerson RG**, Adler JD, Shah, NG, and Brown R. Silent Hypoxia: A Harbinger of Clinical Deterioration in Patients with COVID-19. Am J Emerg Med. 2020; 38(10): p2243.e5-2243.e6. [Case Report] (Published online May 21, 2020)
- 22. Barnabas RV, Brown ER, Bershteyn A, et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial [published online ahead of print, 2020 Dec 8]. Ann Intern Med. 2020;10.7326/M20-6519. [as a member of the Hydroxychloroquine COVID-19 PEP Study Team]
- 23. Ibemere SO, Dubbs SB, Barnhart HX,..., **Wilkerson RG**, et al. Trial design of comparing patient-specific versus weight-based protocols to treat vaso-occlusive episodes in sickle cell disease (COMPARE-VOE). Contemp Clin Trials. 2020;101:106252. doi:10.1016/j.cct.2020.106252.
- 24. Allen B, Christenson R, Cohen S,... Wilkerson RG, et al. Diagnostic Performance of High Sensitivity Cardiac Troponin T Strategies and Clinical Variables in a Multisite United States Cohort. Circulation. 2021;143(17):1659-1672. (ePublished January 21, 2021)
- 25. Gatz JD, Gingold D, Lemkin D, Wilkerson RG. Association of Resident Shift Length with Procedural Complications. J Emerg Med. 2021 May 15;S0736-4679(21)00170-0
- 26. Rosenbaum S, **Wilkerson RG**, Winters ME, et al. Clinical Practice Statement: What is the Emergency Department Management of Patients with Angioedema Secondary to an ACE-Inhibitor? J Emerg Med. 2021 May 15;S0736-4679(21)00182-7
- 27. Kellum JA, et al. Use of Biomarkers to Identify Acute Kidney Injury to Help Detect Sepsis in Patients With Infection. Crit Care Med. 2021; 49(4):e360-e368
- 28. Rodriguez RM, Torres JR, Chang AM,... Wilkerson RG, et al. The Rapid Evaluation of COVID-19 Vaccination in Emergency Departments for Underserved Patients Study. Ann Emerg Med. 2021 (ePublished May 30, 2021)
- 29. Dodd KW, Zvosec DL, Hart MA, et al. Electrocardiographic Diagnosis of Acute Coronary Occlusion Myocardial Infarction in Ventricular Paced Rhythm Using the Modified Sgarbossa Criteria. Ann Emerg Med. 2021 (ePublished Jun 23, 2021) [collaborator PERFECT Study Investigator]
- 30. Wiltjer R, Wilkerson RG. Overview of Autism. EM Reports 2021; 42(15):1-12 [not indexed in PubMed]
- 31. Molinari L, Heskia F, Peerapornratana S, et al. Limiting Acute Kidney Injury Progression In Sepsis: Study Protocol and Trial Simulation. Crit Care Med. 2021;49(10):1706-1716. [as a Sapphire and Protocolized Care for Early Septic Shock (ProCESS) Investigator]
- 32. O'Brien MP, Forleo-Neto E, Musser BJ, et al. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med. 2021;385(13):1184-1195. [as a member of the Covid-19 Phase 3 Prevention Trial Team]
- 33. Ford E, **Wilkerson RG**. Bilateral Hyphema- An Unexpected Complication of Exercise Resistance Band Use: A Case Report. J Emerg Med. (ePublished Dec. 23, 2021)
- 34. **Wilkerson RG**, Moellman JJ. Hereditary Angioedema. Emerg Med Clin North Am. 2021; In-Press October 29, 2021 [indexed in PubMed]
 - a. Reprinted as: **Wilkerson RG**, Moellman JJ. Hereditary Angioedema. *Immunol Allergy Clin North Am*. 2023;43(3):533-552.

- 35. **Wilkerson RG**, Winters ME. Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema. Emerg Med Clin North Am. 2021; In-Press October 29, 2021 [indexed in PubMed]
 - a. Reprinted as: **Wilkerson RG**, Winters ME. Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema. *Immunol Allergy Clin North Am*. 2023;43(3):513-532.
- 36. **Wilkerson RG.** Drug Hypersensitivity Reactions. Emerg Med Clin North Am. 2021; In-Press October 29, 2021 [indexed in PubMed]
 - a. Reprinted as: **Wilkerson RG**. Drug Hypersensitivity Reactions. *Immunol Allergy Clin North Am*. 2023;43(3):473-489.
- 37. O'Brien MP, Forleo-Neto E, Sarkar N, et al. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection. JAMA. 2022;327(5):432-441. [as a member of the Covid-19 Phase 3 Prevention Trial Team]
- 38. McNeilly B, **Wilkerson RG.** Not Feeling Swell: SVC Syndrome falsely attributed to COVID-19 Vaccine Reaction. J Emerg Med. (ePublished February 6, 2022)
- 39. Rosenblatt LS, King SA, Callahan ME, and **Wilkerson RG.** Which Way Would You Slice It? Evaluation of 3 Education Models for the Loop Drainage Technique. Med Sci Educ. 2022;32(2):481-494
- 40. Eswaran V, Chang AM, **Wilkerson RG**, et al. Facemasks: Perceptions and use in an ED population during COVID-19. Plos One. 2022;17(4):e0266148.
- 41. Lurie T, Bonin N, Rea J, Tuteja G, Dezman Z, **Wilkerson RG**, Buganu A, Chasm R, Haase DJ, Tran QK. Patterns of Opioid Prescribing in Emergency Departments During the Early Phase of the COVID-19 Pandemic. Am J Emerg Med. 2022; 56:63-70
- 42. Marshall JD, Heavner JJ, Olivieri PP, Van Ryzin HK, Thomas J, Annous Y, **Wilkerson RG**. Length of Stay and Hospital Cost Reductions After Implementing Bedside Percutaneous Ultrasound Gastrostomy (PUG) in a Critical Care Unit. J Intensive Care Med. 2022;37(12):1667-1672.
- 43. **Wilkerson RG**, Lowie B. Lower Gastrointestinal Bleeding. EM Reports 2022; 43(11):121-131 [not indexed in PubMed]
- 44. Snavely AC, Paradee BE, Ashburn NP,... Wilkerson RG,...et al. Derivation and validation of a high sensitivity troponin-T HEART pathway [published online ahead of print, 2022 Nov 16]. *Am Heart J.* 2022;256:148-157.
- 45. Ashburn NP, Snavely AC, O'Neill JC, Allen BR, Christenson RH, Madsen T, Massoomi MR, McCord JK, Mumma BE, Nowak R, Stopyra JP, Huis in't Veld M, **Wilkerson RG**, Mahler SA. Performance of the European Society of Cardiology 0/1-Hour Algorithm With High-Sensitivity Cardiac Troponin T Among Patients With Known Coronary Artery Disease. *JAMA Cardiology*. 2023;8(4):347-356.
- 46. Prowle JR, Artigas A, Bagshaw SM, Forni LG, Heung M, Hoste E, Marlies O, Koyner JL, Chawla L, Kampf JP, Kwan T, McPherson P, Kellum JA. Serial Urinary C-C Motif Chemokine Ligand 14 and Risk of Persistent Severe Acute Kidney Injury. Crit Care Explor. 2023 Mar 1;5(3):e0870. [as a Sapphire Investigator]
- 47. Neumann JT, Twerenbold R, Ojeda F, et al. Personalized diagnosis in suspected myocardial infarction [published online ahead of print, 2023 May 2]. *Clin Res Cardiol*. 2023;10.1007/s00392-023-02206-3. [As a member of the Artemis Study Group]

- 48. Williams Roberson S, Nwosu S, Collar EM, et al. Association of Vitamin C, Thiamine, and Hydrocortisone Infusion With Long-term Cognitive, Psychological, and Functional Outcomes in Sepsis Survivors: A Secondary Analysis of the Vitamin C, Thiamine, and Steroids in Sepsis Randomized Clinical Trial [published correction appears in JAMA Netw Open. 2023 Apr 3;6(4):e2312173]. *JAMA Netw Open.* 2023;6(2):e230380. Published 2023 Feb 1. [As a VICTAS Investigator]
- 49. Popp L, Ashburn N, Snavely A,..., **Wilkerson R**, et al. Race Differences in Cardiac Testing Rates for Patients with Chest Pain in a Multisite Cohort. *Acad Emerg Med*. 2023;30(10):1020-1028.
- 50. Wilkerson RG, Annous Y, Farhy E, et al. Home Pulse Oximetry Monitoring during the COVID-19 Pandemic: An Assessment of Patient Engagement and Compliance. *Health Policy Technol*. 2023;12(3):100776
- 51. Malley BE, Yabes JG, Gimbel E, et al. Impact of adherence to procalcitonin antibiotic prescribing guideline recommendations for low procalcitonin levels on antibiotic use. *BMC Infect Dis.* 2023;23(1):30. Published 2023 Jan 19. [As a ProACT Investigator]
- 52. Tanabe P, Ibemere S, Bosworth H,... **Wilkerson G**, et al. A Comparison of the effect of patient-specific vs. weight-based protocols to treat vaso-occlusive episodes (VOE) in the emergency department. *Acad Emerg Med.* 2023;30(12):1210-1222.
- 53. Supples MW, Snavely AC, Ashburn NP,... Wilkerson RG, et al. Performance of the 0/2-Hour hs-cTnT Accelerated Diagnostic Protocol in a Multisite United States Cohort. *Acad Emerg Med.* 2024;31(3):239-248.
- 54. Glick Z, **Wilkerson RG**. Ruptured Abdominal Aortic Aneurysms. *EM Reports*. 2023; 44(22):253-264 [not indexed in PubMed]
- 55. Supples MW,...Wilkerson RG, et al. Sex and Race Differences in the Performance of the European Society of Cardiology 0/1-Hour Algorithm with High-Sensitivity Troponin T. Clin Card. (Accepted 11/15/2023)
- 56. European Society of Cardiology 0/1-Hour Algorithm (hs-cTnT) Performance Across Distinct Age Groups. *Heart*. (Accepted 2/3/2024)
- 57. Ashburn NP, Snavely AC, ... **Wilkerson RG**, Mahler SA. Performance of the European Society of Cardiology 0/1-hour algorithm with high-sensitivity cardiac troponin T at 90 days among patients with known coronary artery disease. *Am J Emerg Med*. 2024;79:111-115.

<u>Correspondence/Letters to the Editor</u> [all are listed in PubMed]

- 58. **Wilkerson RG**, Stone MB. Ultrasound Identification of Patella Fracture. Wilderness Envir Med 2009;20:92-93 [case report letter to the editor]
- 59. **Wilkerson RG**. Association of Trichomonas Infection with Gonorrhea or Chlamydia. J Emerg Med 2010; Jan 29. [Epub] [letter]
- 60. Wilkerson RG. Treatment of Acquired Angioedema. Mayo Clin Proc 2010; 85:101
- 61. **Wilkerson RG**, Butler KH and Witting MD. Emergency Cricothyroidotomies for Trauma: further considerations. Am J Emerg Med 2013; 31:990-1 [letter]
- 62. **Wilkerson RG**, Hayes BD. Letter in response to "MDMA-induced angioedema treated with icatibant". Clin Tox 2016; 54(3):293 [letter]
- 63. Adebayo O, **Wilkerson RG**. Response to: "Fresh-frozen plasma in ACE inhibitor induced angioedema- so close and yet so far". Am J Emerg Med 2017; 35(2):346-347 [letter]

- 64. Yu S, **Wilkerson RG**. Facebook: A Last Resort for Patient Contact. Am J Emerg Med 2017;35(9):1375-1376 (ePub March 18, 2017) [correspondence]
- 65. **Wilkerson RG**, Martinelli AN, Oliver WD. Treatment of Angioedema Induced by Angiotensin-Converting Enzyme Inhibitor. J Emerg Med. May 2018. [letter]
- 66. **Wilkerson RG**, Dakessian A, Moellman JJ, et al. Clinical trial of C1-INH for treatment of ACEi-induced angioedema. *Am J Emerg Med*. (Available online 11 April 2023) [letter]

<u>Professional Organization Newsletters</u>

- 1. Manoach S, **Wilkerson RG**, Russo CM, Charchaflieh J. Case Report: A 12-Month-Old Girl With Partial Airway Obstruction Caused by an Esophageal Coin. ASCCA (American Society of Crit. Care Anesthesiologists) Interchange 2010; 21:13-14
- 2. Del Ninno T, Khoujah D, **Wilkerson RG**. Take Home Naloxone. EM Resident. June/July 2017
- 3. Lee R, Wilkerson RG. Contrast Induced nephropathy. EM Resident. Oct/Nov 2018
- 4. **Wilkerson RG**, Annous Y, Hasbini Y. Plus One- Care of the Pregnant Trauma Patient. EM Resident. Aug/Sep 2020
- 5. Annous Y, Aboabdo M, **Wilkerson RG**. Resident Corner Applying to Residency in Emergency Medicine Amid the COVID-19 Pandemic: How Will International Medical Graduates Be Affected? Maryland ACEP Newsletter Summer 2020

Front Matter

- 1. Baugh CW, **Wilkerson RG**. Preface: Observation medicine: Providing Safe and Cost-Effective Care Beyond the Emergency Department. Emerg Med Clin North Am. 2016; 34(2):xvii-xviii
- 2. **Wilkerson RG**, Suau S. Preface: Allergic and Immunologic Emergencies. Emerg Med Clin N Am. 2022;40(1):xv-xvi.
- 3. Wilkerson RG, Suau S. Preface: Anaphylaxis, Angioedema, and Other Immunologic Emergencies. *Immunol Allergy Clin North Am.* 2023;43(3):xiii-xiv.

Book Chapters

- 1. **Wilkerson RG**, Approach to the Patient with Ascites, In: AFEM Handbook of Acute and Emergency Care. Wallis LA and Reynolds TA, eds. Oxford University Press–Southern Africa. 2013
- 2. **Wilkerson RG**, Puncture Wounds, In: Avoiding Common Errors in Emergency Medicine. Mattu A, Chanmugam AS, Swadron SP, et al., eds. Lippincott, Williams and Wilkins. 2017
- 3. Wilkerson RG, Moellman J. Angioedema. In: Mattu A and Swadron S, ed. CorePendium. Burbank, CA: CorePendium, LLC. https://www.emrap.org/corependium/chapter/recgmcfxPSDNkQRTU/Angioedema. Updated November 14, 2019. Accessed November 14, 2019.
- 4. **Wilkerson RG.** Immune System Disorders. In: Dr. Carol Rivers' Preparing for the Written Board Exam in Emergency Medicine 10th Ed. Dietrich, Ann editor. Ohio ACEP. 2020.

- 5. Gaddis GM, Pearson CL, **Wilkerson RG.** Defining a Resident-Level Research/Scholarly Activity Project, In: Resident Research and Scholarly Activity- A Primer. Paxton JH, ed. ACEP Publishing. 2021
- 6. Paxton JH, **Wilkerson RG**, Bhasin A, et al. How to Properly Design and Conduct a Retrospective Study, In: Resident Research and Scholarly Activity- A Primer. Paxton JH, ed. ACEP Publishing. 2021
- 7. **Wilkerson RG.** Immune System Disorders. In: Dr. Carol Rivers' Preparing for the Written Board Exam in Emergency Medicine 11th Ed. Mattu, Amal editor. Ohio ACEP. 2023.
- 8. **Wilkerson RG**, Cutaneous Radiation Syndrome, In: Tinitanalli App (pending final publication)
- 9. **Wilkerson RG**, Acute Radiation Syndrome, In: Tinitanalli App (pending final publication)
- 10. Wilkerson RG, Rhabdomyolysis, In: Tinitanalli App (pending final publication)
- 11. **Wilkerson RG**, Plantar Puncture Wounds, In: Avoiding Common Errors in Emergency Medicine. Winters ME, et al., eds. Lippincott, Williams and Wilkins. 2024 (pending final publication)
- 12. **Wilkerson RG**, Ketamine for Procedural Sedation and Pain Management in the Emergency Department, In: Avoiding Common Errors in Emergency Medicine. Winters ME, et al., eds. Lippincott, Williams and Wilkins. 2024 (pending final publication)
- 13. **Wilkerson RG**, Management of Acute Pain in Patients on Buprenorphine, In: Avoiding Common Errors in Emergency Medicine. Winters ME, et al., eds. Lippincott, Williams and Wilkins. 2024 (pending final publication)

Professional Organization Reports

1. Mannerings A, Stader D, Weiner S, Wilkerson G, et al. Overdose Risk in the ED 2024. The Naloxone Project. Available at: https://www.naloxoneproject.com/s/Overdose-Risk-in-the-ED-2024-02-22.pdf (Feb 2024)

Web-Based Journal Articles

- Wilkerson RG, Sinert R. Trichomoniasis. eMedicine: Emergency Medicine, 2006. http://www.emedicine.com/emerg/topic613.htm
 Also, update in 2008, 2009, 2010 and 2011
- 2. **Wilkerson RG**, Sinert R. Periorbital Infections. eMedicine: Emergency Medicine, 2006. http://www.emedicine.com/emerg/topic415.htm Also, update in 2008, 2009, 2010 and 2011
- 3. **Wilkerson RG**, Doty CI. Ménière's Disease. eMedicine: Emergency Medicine, 2008. http://www.emedicine.com/emerg/topic308.htm Also, update in 2009, 2010
- 4. Stephens NB, **Wilkerson RG**. Relapsing Fever in Emergency Medicine. Medscape Reference. Updated December 19, 2013. Available at: http://emedicine.medscape.com/article/787000-overview.
- 5. **Wilkerson RG,** Nappe TM. Methemoglobinemia. 2019 Jan 13. Statpearls [Internet]. Treasure Island (Fl): Statpearls Publishing; 2018 Jan-. Available From http://www.ncbi.nlm.nih.gov/books/nbk537317/ Pubmed PMID: 30726002.

Multimedia

- 1. **Wilkerson RG**, "Upper Extremity DVT", EMedHome EMCast, http://www.emedhome.com/cme_emcast_list.cfm, March 2014
- 2. **Wilkerson RG**, "Anaphylaxis", EMedHome EMCast, http://www.emedhome.com/cme_emcast_list.cfm, November 2014
- 3. **Wilkerson RG**, "The Inside Scoop in Icatibant", EM:RAP https://www.emrap.org/, March 2016
- 4. **Wilkerson RG**, "Use of TXA in EM", EMedHome EMCast, http://www.emedhome.com/cme_emcast_list.cfm, April 2016
- 5. Wilkerson RG, "Angioedema", ERCast http://blog.ercast.org/, May 2016
- 6. **Wilkerson RG**, "Sickle Cell Disease", EMedHome EMCast, http://www.emedhome.com/cme_emcast_list.cfm, February 2017
- 7. **Wilkerson RG**, "The UMMC Experience: Take Home Naloxone", Maryland Hospital Association Webinar Series; July 2017
- 8. **Wilkerson RG**, "Initiation of Buprenorphine in the ED", EMedHome EMCast, http://www.emedhome.com/cme_emcast_list.cfm, November 2017
- 9. **Wilkerson RG**, "Angioedema", EMedHome EMCast, http://www.emedhome.com/cme_emcast_list.cfm, February 2018
- 10. **Wilkerson RG**, "Management of the Cirrhotic Patient", EMedHome EMCast, http://www.emedhome.com/cme_emcast_list.cfm, February 2018
- 11. **Wilkerson RG**, "Paradigm Shifts in Care of Patients with Sickle Cell Disease", Paradigm Shifts: the official podcast of the National Foundation of Emergency Medicine https://nfoem.com/podcasts/, 2019
- 12. **Wilkerson RG**, "Caring for the Sick Sickle Cell Patient", EMedHome EMCast, http://www.emedhome.com/cme_emcast_list.cfm, December 2021
- 13. **Wilkerson RG**, "Review of Guidelines for Angioedema," EMedHome EMCast, http://www.emedhome.com/cme_emcast_list.cfm, March 2022
- 14. Wilkerson RG, "Firework Safety," WBAL Radio, July 4, 2023
- 15. **Wilkerson RG**, "Spontaneous Bacterial Peritonitis," EMedHome EMCast, http://www.emedhome.com/cme_emcast_list.cfm, 2024 (pending release)

Abstracts, Posters, & Oral Presentations

- 1. Amitai A, **Wilkerson RG**, Roblin P, Mittal R, Arquilla B. Disaster Preparedness: Training Outcomes for Hospital Staff. Poster Presentation New York ACEP Scientific Assembly 2007
- 2. **Wilkerson RG**. Corneal Abrasion. Photo Presentation San Francisco SAEM National Meeting 2006
- 3. Shetty S, Arquilla B, Weiner S, Soghoian S, **Wilkerson G**, and Roblin P. Disaster Training via Annual Workshops in India. Poster Presentation WADEM 16th World Congress on Disaster and Emergency Medicine 2009
 - a. Shetty S, Arquilla B, Weiner S, Sogholan S, **Wilkerson G**, Roblin P. (M12) Disaster Training via Annual Workshops in India. Prehospital Disaster Medicine. 2009;24(2):s125.
- 4. Kenez EL and **Wilkerson RG**. Photo Presentation- A Curious Case of Abdominal Pain. AAEM 21st Annual Scientific Assembly March 2015, Austin, Texas.

- 5. Adams A, Roggio A and **Wilkerson RG**, Sonographic assessment of inadvertent vascular puncture risk during paracentesis using the traditional landmark approach. 19th Annual Mid-Atlantic SAEM Regional Meeting. Feb 28, 2015. Washington DC. (Oral presentation given by Ainsley Adams) SAEM National Meeting May 12-15, 2015 San Diego, CA (Oral presentation given by Anthony Roggio)
- 6. Adams, A, Roggio, A, & Wilkerson, G. (2015). 138. Sonographic Assessment Of Inadvertent Vascular Puncture Risk During Paracentesis Using The Traditional Landmark Approach. Academic Emergency Medicine, 22(S1), S67.
- 7. Adams A, Roggio A and **Wilkerson RG**, Sonographic assessment of inadvertent vascular puncture risk during paracentesis using the traditional landmark approach. Ann Emerg Med. 2015; 66(4S): S132-3 Presented at 2015 ACEP Scientific Assembly Research Forum in Boston, Massachusetts by Ainsley Adams
- 8. Parker BM, Euerle B and **Wilkerson RG**. Photo Presentation- Lip Abscess Mimicking Angioedema. Presented at AAEM 22nd Annual Scientific Assembly February 2016, Las Vegas, NV
- 9. Spangler R, Cotter B, del Ninno T and **Wilkerson RG**. Impact of a Choosing Wisely Based Educational Initiative in the Emergency Department. Abstract presented at 2016 ACEP Research Forum in Las Vegas, NV
- 10. Barstow L, Hines M, Logan J, **Wilkerson RG**, Callahan M, Gingold D, del Ninno T, Willis G. Early subcutaneous insulin glargine plus standard of care for treatment of diabetic ketoacidosis. Poster presentation at American Society of Health System Pharmacists (ASHP) Midyear Clinical Meeting, December 2016, Las Vegas, NV
- 11. del Ninno T, Zhang J, Romeo M, Chen J and **Wilkerson RG**. Comparative Usability Study of Naloxone Autoinjector versus Improvised Intranasal Delivery System in an At-Risk Population. Mediterranean Emergency Medicine Conference, September 2017, Lisbon, Portugal
 - a. *Selected as a Top 20 Outstanding Abstract
- 12. **Wilkerson RG**, Pustavoitau A, Carolan H, Goldwasser E, Benner N and Fischer C. Percutaneous Ultrasound Gastrostomy: Demonstrating Proof of Concept in a Human Cadaver Model. Society of Critical Care Medicine Critical Care Congress, February 2018, San Antonio, Texas.
- 13. Spitzer J, DiRocco D, Morton I, **Wilkerson RG**. Poster 2761 Comparison of Residents' Attitudes and Knowledge About Opioid Use Disorder: A Cross-Sectional Study. American Psychiatric Association Annual Meeting, May 2018, New York, New York.
- 14. Tran K, del Ninno T, Baer MR, Law J, **Wilkerson RG**. Poster 57 Effect of Guidelines for the Care of Patients with Sickle Cell Disease Vaso-occlusive Crisis. AAEM 24th Annual Scientific Assembly April 2018, San Diego, CA
- 15. del Ninno T, Martinez J, **Wilkerson RG**. Poster 125 Unresponsive in an Alley: An ECG Diagnosis. AAEM 24th Annual Scientific Assembly April 2018, San Diego, CA
- 16. Yu S, Schroeder L, del Ninno T, Wilkerson RG. Comparison of Physician versus Nurse assessment of Clinical Opiate Withdrawal Scale (COWS) Evaluation Using Video Simulation. Oral Abstract Presentation at 2018 ACEP Research Forum October, 2018; San Diego, CA
- 17. DiRocco D, Morton I, Spitzer J, **Wilkerson RG**, Welsh C, Weintraub E. Comparison of Residents' Attitudes and Knowledge About Opioid Use Disorder: One Year Follow Up.

- American Academy of Addiction Psychiatry (AAAM) 29th Annual Meeting and Scientific Symposium December 2018; Bonita Springs, FL
 - a. American Journal on Addictions 28 (3), 175
- 18. Ali K, Bruns BR, Liu LS, **Wilkerson RG**. A Cross Sectional Analysis of Current Tranexamic Acid Use in US Trauma Centers. The London Trauma Conference. December 2018; London, UK
 - a. Ali K, **Wilkerson G**, Bruns BR, Liu L. A Cross-Sectional Analysis of Current Tranexamic Acid Use in US Trauma Centers. *Scand J Trauma Resusc Emerg Medicine* 2019, 27(Suppl 1):66
- 19. Wilkerson RG, Carolan H, Goldwasser E, Kent J, Keffer A, Tropello S. Percutaneous Tracheostomy Using Coaptative Ultrasound Methods and Systems. Society of Critical Care Medicine (SCCM) 2019 Critical Care Congress. February 2019; San Diego, CA
- 20. Yu M, **Wilkerson RG**. A Retrospective Review of the Presentation, Management, and Outcomes of Peritonsillar Abscess Presenting to the Emergency Department. AAEM 25th Annual Scientific Assembly March 2019, Las Vegas, NV
- 21. Chiang C, del Ninno T, Sewaralthahab S, Garbus B, Baer M, Law J, **Wilkerson RG**. Analgesic Dosing for Sickle Cell Vaso-Occlusive Crises in the ED and its Effect on Rate of Admission. AAEM 25th Annual Scientific Assembly March 2019, Las Vegas, NV
- 22. Gatz JD, Gingold D, **Wilkerson RG**. 113 Association of Resident Shift Length With Procedural Performance. *Ann Emerg Med*. 2019; 74(4S): S46
 - a. Presented at 2019 ACEP Scientific Assembly Research Forum in Denver, CO by Daniel Gingold
- 23. Schwartz A, Weingrad A, Dupont E, Baer MR, Law J, Callahan C, **Wilkerson RG**. Association of Time to Initial Emergency Department Analgesia with Rate of Admission in Patients with Uncomplicated Sickle Cell Disease Vaso-Occlusive Crises. *Blood* 2019; 134 (Suppl 1): 2307
 - a. Presented at The American Society of Hematology (ASH) 61st Annual Meeting and Exposition. December 2019; Orlando, FL
- 24. **Wilkerson RG**, Tropello S, Carolan H, Goldwasser E, Kent J, Barasch, N. Validating a Memory Shaped Nitinol Pigtail Guidewire for Coaptative Ultrasound Methods and Systems. Society of Critical Care Medicine (SCCM) 2020 Critical Care Congress. February 2020; Orlando, FL
- 25. Rosenblatt L, King S, Callahan M, **Wilkerson RG**. Which Way Should You Slice it?: Evaluating Educational Models for Teaching Loop Drainage Technique. Emergencies in Medicine Conference GREAT Abstracts. March 2020. Park City, UT
 - a. Rosenblatt L, King S, Callahan M, **Wilkerson RG**. Evaluating Educational Models for Teaching Loop Drainage Technique. *J Emergencies, Trauma, Shock*. 2021;14(1):71.
- 26. **Wilkerson RG**, Dupont E, Callahan CW. Development of a Sickle Cell Disease Patient Navigation Program and the Impact of Multi-Disciplinary Team Care Plans on Utilization of Hospital-Based Care in Sickle Cell Disease Patients. 16th Annual Maryland Patient Safety Conference. March 2020. Baltimore, MD
 - a. Selected as a Top 20 Submission
- 27. Isaacs R, Aligholizadeh E, **Wilkerson RG**. Evaluating Clinician Adherence to American Association for the Study of Liver Diseases Guidelines for Ascites. Emergencies in Medicine Conference GREAT Abstracts. March 2020. Park City, UT

- a. Isaacs R, Aligholizadeh E, **Wilkerson RG**. American Association Guidelines for Ascites Management:Clinician Adherence. *J Emergencies, Trauma, Shock*. 2021;14(1):68.
- 28. Melati M, Annous Y, Dupont E, Chang J, Callahan CW, Baer MR, Law J, **Wilkerson RG.** Multidisciplinary Team Care Plans for Adult Sickle Cell Disease Patients Identified as Frequent Utilizers. Mid-Atlantic Society for Academic Emergency Medicine (SAEM) Annual Meeting. March 2020; Washington DC
 - a. Lightning Oral Presentation by Mary Melati
- 29. Dupont E, Lasko K, Callahan CW, and **Wilkerson RG**. Implementation of an ED-based Nurse Navigator for Patients with Sickle cell disease. 2020 Clinical Practice Summit March 2020. Baltimore, MD [Accepted but meeting cancelled due to COVID-19]
- 30. Hurst J and **Wilkerson RG**. Impact of an Infusion Center on the Utilization of Hospital Based Care by Patients with Sickle Cell Disease. Blood. 2020; 136(Supplement 1):6-7
 - a. AAEM 26th Annual Scientific Assembly April 2020, Phoenix, AZ [Accepted but meeting cancelled due to COVID-19]
 - b. Oral presentation by Jonathan Hurst (Top 6 abstracts chosen for oral presentation)
- 31. Johnson K, Rosenblatt L, and **Wilkerson RG**. Photo Competition: Double Vision and Headache- Cranial Nerve III Palsy. AAEM 26th Annual Scientific Assembly April 2020, Phoenix, AZ [Accepted but meeting cancelled due to COVID-19]
- 32. Wang T and **Wilkerson RG**. Photo Competition: More Than Meets The Eye: Right Periorbital Injury- Pott's Puffy Tumor. AAEM 26th Annual Scientific Assembly April 2020, Phoenix, AZ [Accepted but meeting cancelled due to COVID-19]
- 33. Melati M, Annous Y, Dupont E, Chang J, Callahan CW, Baer MR, Law J, **Wilkerson RG.** Multidisciplinary Team Care Plans for Adult Sickle Cell Disease Patients Identified as Frequent Utilizers. *Acad Emerg Med.* 2020; 27(S1): S271.
 - a. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2020; Denver, CO [Accepted but meeting cancelled due to COVID-19]
- 34. Allen B, Christenson R, Cohen S, Nowak RM, **Wilkerson RG**, et al. European Society of Cardiology 0/1-Hour High-Sensitivity Troponin Algorithm Performance in a United States Cohort. *Acad Emerg Med.* 2020; 27(S1): S48.
 - a. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2020; Denver, CO [Accepted but meeting cancelled due to COVID-19]
- 35. Allen B, Christenson R, Cohen S, Nowak RM, **Wilkerson RG**, et al. One and Done? Performance of a Single Low High-Sensitivity Troponin Level in a Multisite United States Cohort. Acad Emerg Med. 2020; 27(S1): S8.
 - a. Plenary Presentation at Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2020; [Virtual Presentation by Brandon Allen due to COVID-19]
- 36. Allen B, Christenson R, Cohen S, Nowak R, **Wilkerson G**, et al. Evaluation of European Society of Cardiology 0/1-Hour Algorithm in the Diagnosis of 90-Day Major Adverse Cardiovascular Events: A Multicenter United States Cohort Study. European Society of Cardiology (ESC) Congress 2020. August 2020; Amsterdam, The Netherlands
- 37. Rodriguez R, Torres J, Chang A... Wilkerson G et al. #54 The Rapid Evaluation of COVID-19 Vaccination in Emergency Departments for Underserved Patients Study. *Ann Emerg Med.* 2021; 78(2S): S28.

- 38. Hunt A, Kelly M, **Wilkerson G**, et al. #40 Facemasks: Perceptions and Use in an Emergency Department Population During COVID-19. *Ann Emerg Med*. 2021; 78(2S):S21
- 39. Haggins A, Miller D, Torres J, Chang AM, **Wilkerson G**, et al. REVVED UP: The Rapid Evaluation of COVID-19 Vaccination in Emergency Departments for Underserved Patients. ACEP Research Forum Special Edition COVID-19. August 2021 (Virtual Presentation)
- 40. Pickering A, Kuhn D, Sutherland M, and **Wilkerson RG**. 964 Understanding Emergency Medicine Residency Programs' Scholarly Activity Requirement Implementation a Mixed Methods Approach. ACEP Research Forum. October 2021; Boston, MA
- 41. Annous Y, Farhy E, Hurst J, Smedley A, and **Wilkerson RG**. 675 Home Pulse Oximetry Monitoring for Patients with Suspected COVID-19: A Pilot Assessment of Patient Engagement and Compliance. ACEP Research Forum. October 2021; Boston, MA
 - a. Annous Y, Farhy E, Hurst J, Smedley A, Wilkerson RG. 160 Home Pulse Oximetry Monitoring for Patients With Suspected COVID-19: A Pilot Assessment of Patient Engagement and Compliance. *Ann Emerg Med*. 2021;78(4):S64-S65. doi:10.1016/j.annemergmed.2021.09.171
- 42. Auville K, Coleman B, Lasko K, Wilkerson G. COVID-19 Vaccine Hesitancy In Emergency Department Patients: An Analysis Of University of Maryland Medical Center Data From The REVVED-UP Study. UMSOM: 44th Annual Medical Student Research Day. November 2021; Baltimore, MD
- 43. Orkoulas-Razis D, Bishop N, Dupont E, Baer MR, **Wilkerson RG**, Law J. Impact of the COVID-19 Pandemic on Acute Care Visits for Patients with Sickle Cell Disease. American Society of Hematology (ASH) 63rd Annual Meeting and Exposition. December 2021; Atlanta, GA
 - a. Orkoulas-Razis D, Bishop N, Dupont E, Baer MR, **Wilkerson RG**, Law JY. Impact of the COVID-19 Pandemic on Acute Care Visits for Patients with Sickle Cell Disease. *Blood*. 2021;138(Supplement 1):3097.
- 44. Annous Y, Marshall J, Heavner J, Olivieri P, Abdulmahdi M, **Wilkerson RG**. Percutaneous Ultrasound Gastrostomy (PUG) Reduces Time to Gastrostomy Tube Placement in the ICU. Society for Critical Care Medicine 51st Critical Care Congress. February 2022; San Juan, Puerto Rico (Accepted)
 - a. Annous Y, Marshall J, Heavner J, Olivieri P, Abdulmahdi M, Wilkerson RG. 586 Percutaneous Ultrasound Gastrostomy Reduces Time to Gastrostomy Tube Placement in the ICU. *Crit Care Med.* 2022;50(1):285.
- 45. O'Neill JC, Ashburn NP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, **Wilkerson RG**, Mumma BE, Madsen T, Stopyra JP, Mahler SA. Performance of the ESC 0/1-Hour Algorithm in Patients with Known Coronary Artery Disease.
 - a. Plenary Presentation at Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2022; New Orleans, LA
 - b. O'Neill JC, Ashburn NP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, **Wilkerson RG**, Mumma BE, Madsen T, Stoprya JP, Mahler SA. #2 Performance of the ESC 0/1-Hour Algorithm in Patients with Known Coronary Artery Disease. *Acad Emerg Med.* 2022;29(S1):S8-S9

- 46. Stopyra JP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, Mumma B, Wilkerson RG, Madsen T, O'Neill JC, Ashburn NP, and Mahler SA. Comparison of Chest Pain Pathways Used with High Sensitivity Troponin. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2022; New Orleans, LA
 - a. Selected as a Top 100 Abstract
 - b. Stopyra JP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, Mumma B, **Wilkerson RG**, Madsen T, O'Neill JC, Ashburn NP, and Mahler SA. #27 Comparison of Chest Pain Pathways Used with High Sensitivity Troponin. *Acad Emerg Med.* 2022;29(S1):S20
- 47. Stopyra JP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, Mumma B, Wilkerson RG, Madsen T, O'Neill JC, Ashburn NP, and Mahler SA. Derivation and Validation of a High Sensitivity Troponin-T HEART Pathway. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2022; New Orleans, LA
 - a. Selected as a Top 100 Abstract
 - b. Stopyra JP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, Mumma B, **Wilkerson RG**, Madsen T, O'Neill JC, Ashburn NP, and Mahler SA. #29 Derivation and Validation of a High Sensitivity Troponin-T HEART Pathway. *Acad Emerg Med.* 2022;29(S1):S21
- 48. Popp LM, Ashburn NP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, Wilkerson RG, Mumma BE, Madsen T, O'Neill JC, Stopyra JP, Mahler SA. Race Differences in Adverse Cardiac Event, Catheterization, and Revascularization Rates in ED Patients with Chest Pain. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2022; New Orleans, LA
 - a. Selected as a Top 100 Abstract
 - b. Popp LM, Ashburn NP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, **Wilkerson RG**, Mumma BE, Madsen T, O'Neill JC, Stopyra JP, Mahler SA. #36 Race Differences in Cardiac Testing Rates for Patients With Chest Pain in a Multisite Cohort. *Acad Emerg Med*. 2022;29(S1):S24-S25
- 49. Ashburn NP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, **Wilkerson RG**, Mumma BE, Madsen T, O'Neill JC, Stopyra JP, Mahler SA. Performance of the ESC 0/1-Hour Algorithm Varies by Age in a Multisite US Cohort. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2022; New Orleans, LA
 - a. Selected as a Top 100 Abstract
 - b. Ashburn NP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, Wilkerson RG, Mumma BE, Madsen T, O'Neill JC, Stopyra JP, Mahler SA. #31 European Society of Cardiology 0/1-Hour Algorithm Performance Varies by Age in a United States Cohort. *Acad Emerg Med.* 2022;29(S1):S22
- 50. Ashburn NP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, Wilkerson RG, Mumma BE, Madsen T, O'Neill JC, Stopyra JP, Mahler SA. The ESC 0/1-Hour Algorithm Performs Similarly between Sexes and Races Using High-Sensitivity Troponin T in a Multisite US Cohort. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2022; New Orleans, LA
 - a. Selected as a Top 100 Abstract
 - b. Ashburn NP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, Wilkerson RG, Mumma BE, Madsen T, O'Neill JC, Stopyra JP, Mahler SA. #32

- European Society of Cardiology 0/1-Hour Algorithm Performs Similarly Between Sexes and Races. *Acad Emerg Med.* 2022;29(S1):S23
- 51. O'Neill JC, Ashburn NP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, **Wilkerson RG**, Mumma BE, Madsen T, Stoprya JP, Mahler SA. Performance of the 0/2-hour Accelerated Diagnostic Protocol in a Multisite US Cohort. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2022; New Orleans, LA a. Selected as a Top 100 Abstract
 - b. O'Neill JC, Ashburn NP, Snavely AC, Paradee BE, Allen BR, Christenson RH, Nowak R, **Wilkerson RG**, Mumma BE, Madsen T, Stoprya JP, Mahler SA. #70 Performance of the 0/2-Hour Accelerated Diagnostic Protocol in a Multisite United States Cohort. *Acad Emerg Med.* 2022;29(S1):S41
- 52. Nowak R, Mahler S, Madsen T, Christenson R, **Wilkerson G**, Mumma B, Yi F, Allen B. #101 Differentiating Type 1 from Type 2 Acute Myocardial Infarction in the Emergency Department Using the N-terminal Pro B-type Natriuretic Peptide/High-sensitivity Cardiac Troponin T Ratio. ACEP Scientific Assembly Research Forum. Oct 2022; San Francisco, CA
 - a. Nowak R, Mahler S, Madsen T, Christenson R, **Wilkerson G**, Mumma B, Yi F, Allen B. 101 Differentiating Type 1 from Type 2 Acute Myocardial Infarction in the Emergency Department Using the N-terminal Pro B-type Natriuretic Peptide/High-sensitivity Cardiac Troponin T Ratio. *Ann Emerg Med*. 2022;80(4):S50. doi:10.1016/j.annemergmed.2022.08.125
- 53. Nowak R, Mahler S, Madsen T, Christenson R, **Wilkerson RG**, Mumma B, Yi F, and Allen B. # POS016: Use of the n-terminal pro b-type natriuretic peptide/high-sensitivity cardiac troponin T ratio to differentiate type 1 from type 2 myocardial infarction. European Emergency Medicine Congress. Oct 2022; Berlin, Germany
- 54. Marshall JD, Olivieri P, Heavner JJ, Ryzin HKV, Thomas J, **Wilkerson RG** (4804) Post Hoc Analysis of Implementing Bedside Percutaneous Ultrasound Gastrostomy in a Critical Care Unit: Assessing Adverse Events and Severity of Illness Between Groups. Oct 2022; Nashville, TN
 - a. Marshall JD, Olivieri P, Heavner JJ, Ryzin HKV, Thomas J, **Wilkerson RG**. Post Hoc Analysis of Implementing Bedside Percutaneous Ultrasound Gastrostomy in a Critical Care Unit: Assessing Adverse Events and Severity of Illness Between Groups. *Chest*. 2022;162(4):A2681.
- 55. Wilkerson RG. (80642) Performance of the High-STEACS Early Rule-Out Pathway for High Sensitivity Cardiac Troponin T at 30-Days in a US Population. European Society of Cardiology Congress. August 2023. Amsterdam, The Netherlands.
- 56. Mumma BE, Tran N, Allen BR, Christenson R, Nowak RM, **Wilkerson RG**, Weaver M, Yi F, Mahler SA. 21 Growth Differentiation Factor-15 is Associated With Myocardial Infarction and Death at 30 and 90 Days. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2023; Austin, TX.
 - a. Mumma BE, Tran N, Allen BR, et al. 21. Growth Differentiation Factor-15 is Associated With Myocardial Infarction and Death at 30 and 90 Days. *Acad Emerg Med*. 2023;30(S1):17.
- 57. Snavely AC, Ashburn NP, Allen BR, Christenson C, Nowak RM, **Wilkerson RG**, Mumma BE, Stopyra JP, Mahler SA. 22 European Society of Cardiology 0/1-Hour, High-Sensitivity Troponin T Algorithm Performance for 90-Day Cardiac Events Among

- Patients With Known Coronary Disease. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2023; Austin, TX.
 - a. Snavely AC, Ashburn NP, Allen BR, et al. 22. European Society of Cardiology 0/1-Hour, High-Sensitivity Troponin T Algorithm Performance for 90-Day Cardiac Events Among Patients With Known Coronary Disease. *Acad Emerg Med.* 2023;30(S1):17.
- 58. Montgomery C, Nowak RM, Ashburn NP, Snavely AC, Allen BR, Christenson R, Wilkerson RG, Mumma BE, Stopyra JP, Mahler SA. 91 Sex-Specific High Sensitivity Troponin Thresholds Do Not Rule Out Cardiac Events in Patients With Coronary Disease. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2023; Austin, TX.
 - a. Montgomery C, Nowak RM, Ashburn NP, et al. 91. Sex-Specific High Sensitivity Troponin Thresholds Do Not Rule Out Cardiac Events in Patients With Coronary Disease. *Acad Emerg Med.* 2023;30(S1):50.
- 59. Millard MJ, Ashburn NP, Snavely AC, Allen BR, Christenson R, Nowak RM, Wilkerson RG, Mumma BE, Stopyra JP, Mahler SA. 95 30-Day Performance of High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome, Early Rule-Out Pathway for Cardiac Troponin T in a United States Population. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2023; Austin, TX.
 - a. Millard M, Ashburn NP, Snavely AC, et al. 95. 30-Day Performance of High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome, Early Rule-Out Pathway for Cardiac Troponin T in a United States Population. *Acad Emerg Med.* 2023;30(S1):52.
- 60. Ashburn NP, Snavely AC, Allen BR, Christenson R, Nowak RM, **Wilkerson RG**, Mumma BE, Stopyra JP, Mahler SA. 507 One and Done High-Sensitivity Troponin T Strategy Is Unsafe in Patients With Known Coronary Artery Disease. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2023; Austin, TX.
 - a. Ashburn NP, Snavely AC, Allen BR, et al. 507. One and Done High-Sensitivity Troponin T Strategy Is Unsafe in Patients With Known Coronary Artery Disease. *Acad Emerg Med.* 2023;30(S1):240.
- 61. Supples M, Stopyra JP, Ashburn NP, Allen BR, Christenson R, Nowak RM, Wilkerson RG, Mumma BE, Mahler SA. 509 Performance of the High-Sensitivity Cardiac Troponin T 0/2-hour Accelerated Diagnostic Protocol at 90 days. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2023; Austin, TX.
 - a. Millard M, Ashburn NP, Snavely AC, et al. 95. 30-Day Performance of High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome, Early Rule-Out Pathway for Cardiac Troponin T in a United States Population. *Acad Emerg Med.* 2023;30(S1):52.
- 62. Dakessian A, Yoon I, Lasko K... Wilkerson RG. Use of a Rapid Bedside Semi-Quantitative Test to Detect COVID-19 Immunoglobulin Levels in Vaccinated Immunocompetent Adult Patients. ACEP Research Forum. October 2023; Philadelphia, PA
 - a. Dakessian A, Yoon I, Lasko K...**Wilkerson RG**. 238. Use of a Rapid Bedside Semi-Quantitative Test to Detect COVID-19 Immunoglobulin Levels in

- Vaccinated Immunocompetent Adult Patients. *Ann Emerg Med.* 2023;82(4):S108.
- 63. Harris AW, LaBonte L, Massaccesi G,... Wilkerson RG. Potential Impact of Application of the Canadian Syncope Risk Score. ACEP Research Forum. October 2023; Philadelphia, PA
 - a. Harris AW, LaBonte L, Massaccesi G,... **Wilkerson RG**. Potential Impact of Application of the Canadian Syncope Risk Score. *Ann Emerg Med*. 2023;82(4):S50.
- 64. Bhandari N, Tran NK, Allen BR, Christenson RC, Nowak RM, Wilkerson RG, et al. Su4059 / 4059 Sex Differences in Growth Differentiation Factor-15 and Association With Acute Myocardial Infarction and Death at 90 Days in Emergency Department Patients Presenting With Acute Chest Pain and Normal Troponin Levels. American Heart Association Scientific Sessions. November 2023; Philadelphia, PA
 - a. Bhandari N, Tran NK, Allen BR, Christenson RC, Nowak RM, **Wilkerson RG**, et al. A bstract 14946: Sex Differences in Growth Differentiation Factor-15 and Association With Acute Myocardial Infarction and Death at 90 Days in Emergency Department Patients Presenting With Acute Chest Pain and Normal Troponin Levels. *Circulation*. 2023;148:A14946
- 65. Yamane DP, Jones CW, **Wilkerson RG**, et al. High-Velocity Nasal Insufflation vs Non-Invasive Positive Pressure Ventilation for COPD Exacerbation. Society of Critical Care Medicine (SCCM) Critical Care Congress. January 2024; Phoenix, AZ
 - a. *Selected for a Star Research Award
 - b. Yamane DP, Jones CW, **Wilkerson G**, et al. 42. High-Velocity Nasal Insufflation vs Non-Invasive Positive Pressure Ventilation for COPD Exacerbation. Crit Care Med. 2024;52(1):S21.
- 66. Bui T, Wynne A, **Wilkerson RG**, Salerno A. Correlation Between Tongue Thickness and Distance Skin to Epiglottis as Measured by Ultrasound with BMI. Society for Academic Emergency Medicine (SAEM) Annual Meeting. May 2024; Phoenix, AZ (Accepted)

Major Invited Speeches

Local

- 1. **Wilkerson, R.G.**, "Angioedema", Kings County Hospital/SUNY-Downstate, Brooklyn, NY, October 2009
- 2. **Wilkerson, R.G.**, "Hemoglobinopathies", University of South Florida/Tampa General Hospital Emergency Medicine Grand Rounds, Tampa, FL, March 2011
- 3. **Wilkerson, R.G.**, "Rhabdomyolysis", University of South Florida/Tampa General Hospital Emergency Medicine Grand Rounds, Tampa, FL, June 2011
- 4. **Wilkerson, R.G.**, "Angioedema", University of South Florida/Tampa General Hospital Internal Medicine Morning Conference, Tampa, FL, November 2011
- 5. **Wilkerson, R.G.**, "Kawasaki Disease, Sarcoidosis, & Rheumatic Fever", University of South Florida/Tampa General Hospital Emergency Medicine Grand Rounds, Tampa, FL, February 2012

- 6. Wilkerson, R.G., "Epistaxis, Cavernous Sinus Thrombosis, Rhinitis, & Sinusitis", University of South Florida/Tampa General Hospital Emergency Medicine Grand Rounds, Tampa, FL, April 2012
- 7. **Wilkerson, R.G.**, "Sickle Cell Disease", University of Maryland Emergency Medicine Residency Conference, Baltimore, MD, November 2012
- 8. **Wilkerson, R.G.**, "Adverse Drug Reactions: an introduction for radiation technologists", University of Maryland Medical Center Radiation Technologists Meeting, Baltimore, MD, April 2013
- 9. **Wilkerson, R.G.**, "Introduction to ECGs", University of Maryland Medical Center Nurse Practitioners, Baltimore, MD, May 2013
- 10. **Wilkerson, R.G.**, "Angioedema- There Is More", Grand Rounds, Department of Anesthesia, Mercy Medical Center, Baltimore, MD, October 2013
- 11. **Wilkerson, R.G.**, "Introduction to ECGs II", University of Maryland Medical Center Nurse Practitioners, Baltimore, MD, November 2013
- 12. **Wilkerson, R.G.**, "Approach to Anaphylaxis", University of Maryland Emergency Medicine Residency Intern Orientation, Baltimore, MD, July 2014
- 13. **Wilkerson, R.G.**, "Anaphylaxis & Angioedema", University of Maryland Midtown Campus Internal Medicine Residency Grand Rounds, Baltimore, MD, August 2014
- 14. **Wilkerson, R.G.**, "Introduction to ECGs", University of Maryland Emergency Medicine Medical Student Rotation Conference, Baltimore, MD, September 2014
- 15. **Wilkerson, R.G.**, "Don't Let Your CBRNE Event Become a Disaster", Grand Rounds, Department of Anesthesia, Mercy Medical Center, Baltimore, MD, January 2015
- 16. **Wilkerson, R.G.**, "Approach to Anaphylaxis", University of Maryland Emergency Medicine Residency Intern Orientation, Baltimore, MD, July 2015
- 17. **Wilkerson, R.G.**, "Introduction to ECGs" a 2.5 hour course, University of Maryland School of Nursing Adult-Gerontology Primary Care Nurse Practitioner Program; Baltimore, MD, March 2016
- 18. **Wilkerson, R.G.**, "Approach to Anaphylaxis", University of Maryland Emergency Medicine Residency Intern Orientation, Baltimore, MD, July 2016
- 19. **Wilkerson, R.G.**, "Introduction to ECGs" a 2.5 hour course, University of Maryland School of Nursing Adult-Gerontology Primary Care Nurse Practitioner Program; Baltimore, MD, March 2017
- 20. **Wilkerson, R.G.**, "Take Home Naloxone" Howard County Hospital Department of Emergency Medicine, July 2017
- 21. **Wilkerson, R.G.**, "Introduction to ECGs" a 2.5 hour course, University of Maryland School of Nursing Adult-Gerontology Primary Care Nurse Practitioner Program; Baltimore, MD, March 2018
- 22. **Wilkerson**, **R.G.**, "I Can Narcan", Intern Bootcamp: University of Maryland School of Medicine, Baltimore, MD, May 2018
- 23. Wilkerson, R.G., "The Emergency Department: On the Front Lines of the Opioid Epidemic", Baltimore County Department of Health "Prescribing Drugs Responsibly" Conference, Baltimore, MD, May 2018
- 24. **Wilkerson, R.G.**, "Red Blood Cell Disorders", University of Maryland Emergency Medicine Residency Conference, Baltimore, MD, November 2018
- 25. **Wilkerson, R.G.**, "Responding to the Opioid Epidemic", Mercy Medical Center Grand Rounds for Surgery, Anesthesia & Ob-Gyn, Baltimore, MD, January 2019

- 26. **Wilkerson, R.G.**, "Responding to the Opioid Epidemic", University of Maryland Medical Center, Department of Surgery Grand Rounds, Baltimore, MD, January 2020
- 27. **Wilkerson, R.G.**, "Updates on the Treatment of Sickle Cell Disease", University of Maryland Emergency Medicine Residency Conference, Baltimore, MD, September 2020
- 28. **Wilkerson, R.** G., "Angioedema: A Swelling Epidemic", University of Maryland Family Medicine Residency Conference, Baltimore, MD, April 2021
- 29. **Wilkerson, R.G.**, "Introduction to ECGs" a 2.5-hour course, University of Maryland School of Nursing Adult-Gerontology Primary Care Nurse Practitioner Program; Baltimore, MD, April 2022
- 30. **Wilkerson, R.G.**, "Resiliency & Wellness in Emergency Medicine", University of Maryland Emergency Medicine Residency Conference, Baltimore, MD, June 2022
- 31. **Wilkerson, R.G.**, "Recent Literature on ACE Inhibitor-Induced Angioedema", University of Maryland Emergency Medicine Residency Conference, Baltimore, MD, February 2023
- 32. **Wilkerson, R.G.** and Dubbs, S.B., "Beyond the Pain: Emergencies of Sickle Cell Disease," University of Maryland Emergency Medicine Residency Conference, Baltimore, MD, August 2023
- 33. **Wilkerson**, **R.G.**, "The Opioid Epidemic A Call to Action", University of Maryland Medical Center, Department of Obstetrics & Gynecology Grand Rounds, Baltimore, MD, September 2023

State/Regional

- 34. **Wilkerson, R.G.**, "Explosive Disasters", Kings County Hospital / SUNY Downstate Emergency Medicine Residency Conference, Brooklyn, NY, July 2013
- 35. **Wilkerson, R.G.**, "Anaphylaxis: Don't Let It Take Your Breath Away", Greater Chesapeake Emergency Medicine Combined Conference, Baltimore, MD, September 2013
- 36. **Wilkerson, R.G.**, "Explosive Disasters", Kings County Hospital / SUNY Downstate Emergency Medicine Residency Conference, Brooklyn, NY, July 2014
- 37. **Wilkerson, R.G.**, "Let's Have A Blast: Intro to Explosive Disasters", Kings County Hospital / SUNY Downstate Emergency Medicine Residency Conference, Brooklyn, NY, July 2014
- 38. **Wilkerson, R.G.**, "Don't Let Your CBRNE Event Become a Disaster", Bellevue Hospital Department of Emergency Medicine Grand Rounds, New York, NY, May 2015
- 39. **Wilkerson**, **R.G.**, "Let's Have A Blast: Intro to Explosive Disasters", Bellevue Hospital Department of Emergency Medicine Grand Rounds, New York, NY, May 2015
- 40. **Wilkerson**, **R.G.**, "Explosive Disasters- Let's Have A Blast!", UMBC Paramedic Refresher Course; Baltimore, MD, February 2016
- 41. **Wilkerson, R.G.**, "My Journey on the Gurney", Maryland ACEP, Baltimore, MD, March 2017
- 42. **Wilkerson, R.G.**, "Sickle Cell Disease: Primum non nocere", Grand Round Lecture at Christiana Care Emergency Medicine Residency, Newark, DE, June 2017
- 43. **Wilkerson, R.G.**, "Anaphylaxis- Don't Let It Take Your Breath Away", University Medical Center Hospital Grand Rounds, Washington, DC, November 2017

- 44. **Wilkerson, R.G.**, "Angioedema- Don't Let It Take Your Breath Away", University of Florida- Jacksonville Emergency Medicine Grand Rounds, Jacksonville, FL, November 2017
- 45. **Wilkerson**, **R.G.**, "Blood Products in the ED", Virginia ACEP, The Homestead, VA, February 2019
- 46. **Wilkerson**, **R.G**., "There Will Be Blood: Reversal of the Bleeding Patient on Anticoagulation", Virginia ACEP, The Homestead, VA, February 2019
- 47. **Wilkerson, R.G.**, "Responding to the Opioid Epidemic", Maryland Chapter of the American College of Surgeons Annual Meeting, Annapolis, MD March 2019
- 48. **Wilkerson**, **R.G.**, "Sickle Cell Disease Treatment Strategies: Best Practices & Emerging Therapies", California ACEP Board of Directors Meeting, Sacramento, CA April 2019
- 49. **Wilkerson**, **R.G.**, "Angioedema: A Swelling Epidemic", Grand Round Lecture, Mt. Sinai Hospital, Department of Emergency Medicine, New York, NY September 2019
- 50. **Wilkerson, R.G.**, "Responding to the Opioid Epidemic", Grand Round Lecture, Prisma Health Department of Emergency Medicine, Greenville, SC January 2020
- 51. Wilkerson, R.G., "Be the Change: Improving Care of Sickle Cell Disease", Grand Rounds Lecture, Department of Emergency Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA May 2020 [Zoom Conference due to COVID-19]
- 52. **Wilkerson, R.G.,** Chua, J, Narayanan, S, "Monoclonal Antibody Therapy for COVID-19: Scientific Basis and Ongoing Studies", Maryland Department of Health, March 2021 [Zoom Conference due to COVID-19]
- 53. Wilkerson, R.G., "Caring for Patients with Sickle Cell", Grand Rounds Lecture, Department of Emergency Medicine, Georgetown University/Washington Hospital Center, Washington DC, November 2021
- 54. **Wilkerson**, **R.G.**, "Substance Abuse Slingshot", Educational Station at Greater Chesapeake Emergency Medicine Conference, Ellicott City, MD, September 2022
- 55. **Wilkerson**, **R.G.**, "Developing a Winning Research Program", Grand Rounds Lecture, Department of Emergency Medicine, Charleston Area Medical Center, Charleston, WV (virtual), May 2023
- 56. **Wilkerson**, **R.G.**, "Extended Release Buprenorphine", Part of Maryland ACEP Panel with Mustapha Saheed, MD and Drew Fuller, MD. (virtual), January 2024

National

- 57. **Wilkerson, R.G.**, "Angioedema- Your Worst Airway Nightmare", Crashing Patient Conference, Baltimore, MD, October 2013
- 58. **Wilkerson, R.G.**, "Angioedema- Why do we keep treating it all the same?", 21st Annual American Academy of Emergency Medicine Scientific Assembly, Austin, TX, March 2015
- 59. **Wilkerson, R.G.**, "Rhabdo- Where is the evidence?", 21st Annual American Academy of Emergency Medicine Scientific Assembly, Austin, TX, March 2015
- 60. **Wilkerson**, **R.G.**, "Point-Counterpoint- We Should Treat Asymptomatic Hypertension from the ED", 22nd Annual AAEM Scientific Assembly; Las Vegas, NV, February 2016
- 61. **Wilkerson, R.G.**, "Angioedema- What Can We Do?", 22nd Annual AAEM Scientific Assembly; Las Vegas, NV, February 2016
- 62. **Wilkerson, R.G.**, "When the Patient is Me!", Crashing Patient Conference; Baltimore, MD, November 2016

- 63. Wilkerson, R.G., "Stop the Bleed: Hemorrhage in DOAC Therapy", 23rd Annual AAEM Scientific Assembly, Orlando, FL, March 2017
- 64. **Wilkerson, R.G.**, "My Journey on the Gurney", 23rd Annual AAEM Scientific Assembly, Orlando, FL, March 2017
- 65. **Wilkerson, R.G.**, "Sickle Cell Disease- Primum non nocere", 24th Annual AAEM Scientific Assembly; San Diego, CA; April 2018
- 66. **Wilkerson**, **R.G.**, "The Underestimated Cost of the Opioid Crisis", International City/County Management Association National Conference, Baltimore, MD September 2018
- 67. **Wilkerson**, **R.G.**, "There Will Be Blood: Reversal of the Bleeding Patient on a DOAC", 25th Annual AAEM Scientific Assembly; Las Vegas, NV; March 2019
- 68. **Wilkerson, R.G.**, "My Journey on the Gurney", 2020 Rocky Mountain Winter Conference; Breckenridge, CO; February 2020
- 69. **Wilkerson**, **R.G.**; Glassberg, J; Freiermuth, C; Young, H. "SCD and COVID Management in the ED"; ASH/ACEP Webinar; November 2020
- 70. Wilkerson, R.G., "MAT & MAB: Monoclonal Antibodies & Medication Assisted Treatment", Emergency Department Practice Management Association (EDPMA) Virtual Workshop; May 2021
- 71. **Wilkerson**, **R.G.**, "Managing the SICK Sickle Cell Patient", The Crashing Patient Conference; Baltimore, MD; October 2021
- 72. **Wilkerson**, **R.G.**, "Sickle Cell Disease- Complications That Kill", 2022 Rocky Mountain Winter Conference; Steamboat Springs, CO; March 2022
- 73. **Wilkerson**, **R.G.**, "Found Down? Check the Compartments!", The Crashing Patient Conference; Baltimore, MD; November 2022
- 74. **Wilkerson, R.G.,** "Developing an Industry-Funded Clinical Research Program," Society of Critical Care Medicine- Emergency Medicine Research Section Quarterly Meeting; Virtual; October 2023

International

- 75. **Wilkerson, R.G.**, "Chemical Warfare & Disaster Medicine", Kasturba Medical College, Mangalore, India, October 2008
- 76. **Wilkerson, R.G.**, "Radiation & Disaster Medicine", Kasturba Medical College, Mangalore, India, October 2008
- 77. **Wilkerson, R.G.**, "Emergency Sonography Saves Time & Saves Lives", INDUS-EM 2008: 4th Indo-US Emergency Medicine Summit, Mangalore, India, October 2008
- 78. **Wilkerson, R.G.**, "Hazard Vulnerability Analysis", PSG Hospital, Coimbatore, India, October 2009
- 79. **Wilkerson, R.G.**, "HVA & CBRNE", INDUS-EM 2009: 5th Indo-US Emergency Medicine Summit Coimbatore, India, October 2009
- 80. **Wilkerson, R.G.**, "FAST Exam", 3rd Emergency Sonography School, B J Medical College, Ahmedabad, India, November 2009
- 81. **Wilkerson, R.G.**, "Lung Sonography: An Introduction", 3rd Emergency Sonography School, B J Medical College, Ahmedabad, India, November 2009
- 82. **Wilkerson, R.G.**, "Non-Invasive Ventilation for the Emergency Physician", Apollo GlenEagles Hospital Masters in Emergency Medicine Program, Kolkata, India April 2017

- 83. Wilkerson, R.G., "Recognition of the Sick Patient", Apollo GlenEagles Hospital Masters in Emergency Medicine Program, Kolkata, India April 2017
- 84. **Wilkerson**, **R.G.**, "Use of Vasopressors in Sepsis", Apollo GlenEagles Hospital Masters in Emergency Medicine Program, Kolkata, India April 2017
- 85. **Wilkerson**, **R.G.**, "Use of Lactate in Resuscitation", Apollo GlenEagles Hospital Masters in Emergency Medicine Program, Kolkata, India April 2017
- 86. **Wilkerson**, **R.G.**, "Recognition and Management of Shock", Apollo GlenEagles Hospital Masters in Emergency Medicine Program, Kolkata, India April 2017
- 87. **Wilkerson, R.G.**, "Management of Acute Decompensated Heart Failure", Apollo GlenEagles Hospital Masters in Emergency Medicine Program, Kolkata, India April 2017
- 88. **Wilkerson**, **R.G.**, "The Lon Chaney Lecture", Apollo GlenEagles Hospital Masters in Emergency Medicine Program, Kolkata, India April 2017
- 89. **Wilkerson**, **R.G.**, "Angioedema & Anaphylaxis", Apollo GlenEagles Hospital Masters in Emergency Medicine Program, Kolkata, India April 2017
- 90. **Wilkerson, R.G.**, "Introduction to ECG Analysis", Apollo GlenEagles Hospital Masters in Emergency Medicine Program, Kolkata, India April 2017
- 91. **Wilkerson, R.G.**, "Angioedema: Preparing for a Potential Airway Disaster", Inter-American Emergency Medicine Conference, San Jose, Costa Rica May 2017
- 92. **Wilkerson, R.G.**, "Seeing Red: Massive Transfusion in Trauma", Inter-American Emergency Medicine Conference, San Jose, Costa Rica May 2017
- 93. **Wilkerson, R.G.**, "Sickle Cell Disease: Primum non Nocere", Mediterranean Emergency Medicine Conference (MEMC), Lisbon, Portugal September 2017
- 94. **Wilkerson, R.G.**, "Angioedema: The Science Behind Its Treatment", Mediterranean Emergency Medicine Conference (MEMC), Lisbon, Portugal September 2017
- 95. **Wilkerson, R.G.**, "I Feel Swell: Allergy, Anaphylaxis, and Angioedema," Chiang Mai University Hospital, Department of Emergency Medicine, Chiang Mai, Thailand February 2024
- 96. **Wilkerson, R.G.**, "I Feel Swell: Allergy, Anaphylaxis, and Angioedema," Nakhon Pathom Hospital, Department of Emergency Medicine, Nakhon Pathom, Thailand February 2024
- 97. **Wilkerson, R.G.**, "I Feel Swell: Allergy, Anaphylaxis, and Angioedema," Ramathibodi Hospital, Department of Emergency Medicine, Bangkok, Thailand February 2024

Community Engagements

- 98. **Wilkerson, R.G.**, "COVID-19 Vaccine", Maryland Sickle Cell Disease Association Meeting January 2021
- 99. **Wilkerson, R.G.**, "COVID-19, Vaccinations, and Disparities in Healthcare", Healthcare Disparities Webinar, Converted Heart Christian Methodist Church, Calverton, MD, February 2021
- 100. **Wilkerson, R.G.**, et al., "WEBINAR: Monoclonal Antibody Infusions for the Treatment of COVID-19", University of Maryland Medical System, Baltimore, MD, February 2021
- 101. **Wilkerson, R.G.**, "Being an Emergency Physician", Career Day, Roland Park Elementary & Middle School, Baltimore, MD, April 2021

102. **Wilkerson, R.G.**, et al., "WEBINAR: Monoclonal Antibody Treatment for COVID-19", Town of Bowie, MD, May 2021